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ABSTRACT 
ZHUZHU Z. ZHANG: The influence of chromatin state on pluripotency, translocations, 
and gene regulation in human cells 
(Under the direction of Terrence S. Furey) 
 
A human body consists of more than a thousand cell types, each having a unique 
identity and function. Despite their distinct functions, all the different cells contain the 
same genetic information encoded in the human genome. One of the fundamental 
questions in biology is- how does a single genome provide the instruction for different 
cell types? We have learned that only a small part of the genomic information is used in 
each cell, and that the usage of the genome varies in different cells.  The precise 
regulation of the genome usage is the key to cell identity.  
The usage of the genomic information highly depends on whether the DNA 
sequence containing specific information is directly accessible to DNA-binding proteins 
such as transcription factors that read and translate the encoded information. Most of the 
genomic DNA wrapped around histone proteins, forming the nucleosomes. Most DNA-
binding proteins cannot bind to their target DNA sequences if a nucleosome is present. 
Therefore, the nucleosome-depleted regions, “open chromatin”, represent regions of the 
genome that are accessible and the genomic information that is used in the cell. In this 
dissertation, I study the landscape and function of open chromatin, and its role in defining 
cell identity and function.   
I examine the open chromatin architecture in a specific case of cell identity – the
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reestablishment of pluripotency in terminally differentiated cells by reprogramming the cell fate 
(Chapter II). Induced pluripotent stem cells (iPSCs) are reprogrammed from differentiated 
somatic cells. Compared to their naturally existing counterpart embryonic stem cells (ESCs), 
iPSCs have very similar but in many cases slightly altered developmental potential when 
differentiating into other cell types. The cause of the different development potential is poorly 
understood. In this study, I show that the regulatory landscape defined by open chromatin is 
highly similar between hESCs and hiPSCs but differs at a set of key development genes. More 
importantly, the chromatin differences do not appear to affect the transcription profiles at the 
pluripotent state, but instead impact the regulation of transcription upon differentiation.  These 
results suggest that the accessibility of genomic information controlled by chromatin structure 
does not only regulate the cell identity at its current state, but also influence the precise 
regulation of its developmental potential. 
In addition, I describe a high-throughput method I developed for functional annotation of 
the regulatory elements marked by open chromatin (Chapter III). Using this approach, I 
identified 3,428 open chromatin regions associated with enhancer activities in a reporter assay, 
demonstrating the feasibility of functional characterization of several thousand regulatory 
elements in a single experiment of this design. At last, I investigate the role of chromatin 
structure in the development of cancer (Chapter III). The results indicate that characteristic 
chromatin features marked by specific histone modifications may highlight genomic loci that are 
susceptible to chromosomal translocation in hematologic malignancies.
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CHAPTER I: 
INTRODUCTION 
 
An adult human body contains more than 1013 cells [1] that consist of thousands of 
different cell types each with a specific identity performing a specialized function. All cells 
inherit and share the same genome that is contained in the zygote. Therefore, a fundamental 
question in biology is – how does a single genome encode the information required to produce 
the diversity of cell types? More specifically, how is the information accessed and used in 
different cell types, and how is this access regulated? 
The human genome is composed of 3 billion nucleotides of DNA. The genomic DNA, 2 
nanometers in diameter and in total approximately 2-meter long, is tightly packaged in the 
nucleus that is on average 6 micrometers in diameter. To achieve the ~10,000-fold compaction, 
genomic DNA wraps around histone proteins forming nucleosomes, with the nucleosome core 
particle (Figure 1.1) consisting of about 146 base pair (bp) of DNA and an octamer of histone 
proteins. Such “beads on a string” structure is the basic building block of chromatin that is 
organized by many levels of folding. The formation of nucleosomes is not only the first level of 
chromatin organization, it also controls the access of information encoded in DNA in each cell. 
Most proteins that regulate transcription require direct binding to nucleosome-free DNA to 
function [2-5]. Therefore, nucleosome depletion, or the formation of regions of “open 
chromatin”, is a mark of transcription factor binding events and the underlining regulatory 
elements that are specifically accessed and used in each cell type [2-4,6-8].  
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To further understand the regulatory role of chromatin dynamics at the nucleosome level 
in determination and specification of cell identity and function, I examined genome-wide 
chromatin states in human embryonic stem cells (hESCs) and induced pluriopotent stem cells 
(hiPSCs). More specifically, I investigated how subtle differences in the open chromatin 
landscape between the two human pluripotent cell types may lead to different regulation of 
transcription during cellular differentiation (Chapter II). In addition, I developed a high-
throughput method to test the function of regulatory elements dictated by open chromatin on a 
genome-wide scale in a single experiment (Chapter III). Finally, I explored the role of 
chromatin structure and predisposition of specific histone modifications in chromosomal 
translocation prior to oncogenesis (Chapter IV). As an introduction to this dissertation, I review 
the function and identification of open chromatin, detail our current understanding of epigenetic 
reprogramming during hiPSCs production, discuss technologies and obstacles of functional 
annotation of human regulatory elements, and close with a brief description into chromosomal 
translocation in oncogenesis.  
1.1 Chromatin dynamics and transcription regulation 
1.1.1 Open chromatin is a hallmark of active regulatory elements 
The key to the establishment of the cell identity and function is the regulation of the 
usage of information coded in the genome. In eukaryotes, such regulation is controlled largely 
through the regulation of the chromatin state and DNA accessibility. Transcription factors and 
nucleosome compete for DNA-encoded information (Figure 1.1). Nucleosome disruption at 
active regulatory regions is a conserved feature of eukaryotic chromatin [2-4,9-13]. The binding 
of sequence-specific regulatory factors and the recruitment of chromatin remodeling activities at 
promoters, enhancers, silencers, and insulators is typically associated with nucleosome eviction 
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from chromatin in eukaryotic cells [14] [5,15]. Other factors that influence the nucleosome 
stability and positioning include the inherent properties of DNA sequence [16], the activity of 
chromatin remodeling complexes such as SWI/SNF (SWItch/Sucrose NonFermentable) [17], 
transcriptional initiation and elongation by RNA polymerases [18], and the post-translational 
modification of histone proteins [19-21] and incorporation of histone variants [19,22,23]. In any 
given cell type, those mechanisms work together to establish an overall chromatin architecture in 
which regions of open chromatin dictate the accessible part of genome and active regulatory 
elements. Genome-wide mapping and characterization of open chromatin in different cell types 
can provide insights in how the variation in accessibility and utilization of genomic information 
contribute to the specification of different cell identities and functions.  
 
 
Figure 1.1. Open chromatin regions. In most cases, a DNA-binding protein (light blue sphere) 
such as a transcription factor cannot access its binding site (purple box) if it is occupied by a 
nucleosome (dark blue sphere). Therefore, nucleosome depletion is a mark of transcription factor 
binding and active transcription regulation.  
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1.1.2 Genome-wide mapping of open chromatin 
Regions of open chromatin can be identified by deoxyribonuclease (DNase I) 
Hypersensitive site mapping by preferential digestion of nucleosome-free regions [2-4,6,24,25], 
or FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) which probes open 
chromatin through differences in formaldehyde cross-linking efficiency between nucleosomal 
and non-nucleosomal DNA [7,14,26-28].  
DNase I is an endonuclease that cleaves DNA at the phosphodiester linkages of its 
backbone. When the DNA is nucleosomal as it is in chromatin, regions with nucleosome 
depletion is cut preferentially by DNase I which is commonly referred as hypersensitive to 
DNase I cleavage [2-4,6]. DNase I hypersensitivity (DHS) was originally reported at the 
transcription start sites (TSSs) of heat shock genes upon activation in Drosophila, and has since 
been used to detect regions of open chromatin and the underlying regulatory elements.  DHS 
sites mapping can be carried at individual loci or genome-wide via coupling with microarrays 
[24,25,29] or, as in most recent studies, with high-throughput sequencing [7,8,25,30,31].   
FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements) [14,26,28] uses 
differences in formaldehyde cross-linking efficiency between nucleosomal and non-nucleosomal 
DNA to not only detect but also isolate the nucleosome-depleted DNA. Formaldehyde crosslinks 
proteins and DNA in direct contact [32,33]. Within each nucleosome core on average 146 bp 
DNA wraps around an octamer of histone proteins, providing approximately 10 to 15 histone-
DNA interaction sites [34] for potential crosslinking by formaldehyde. In contrast, most DNA-
binding proteins bind to DNA sequences of 5 to 15 bp [35,36], resulting few potential 
crosslinking sites. Therefore, the difference in crosslinking efficiency is used the simple 
procedure of FAIRE to isolate nucleosome-depleted genomic DNA [14,26,28] - chromatin is 
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first cross-linked with formaldehyde, sheared by sonication, and then a phenol-chloroform 
extraction is performed in which nucleosome-free fragments preferentially segregate and are 
enriched in the aqueous phase. The genomic DNA fragments in the aqueous phase can then be 
mapped by microarrays [14,29] or high-throughput sequencing [7,27,31].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 DNase I hypersensitivity and FAIRE detect open chromatin regions that identify 
putative regulatory elements in diverse cell types (A) DNase-seq and FAIRE-seq. (B) DNase I 
hypersensitivity and FAIRE data from seven cell lines surrounding the HNF4A locus (145 kb) 
shows both ubiquitous and cell-type specific open sites that are especially prevalent in HepG2 
cells. Pol II,CTCF, and Myc ChIP-seq peaks that overlap open chromatin are highlighted. (Song 
et al. (2011) Genome Research [7]) 
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More recently, a new assay for probing open chromatin regions, ATAC-seq, was reported 
based on direct in vitro transposition of sequencing adaptors into native chromatin [37]. 
Transposons have been shown to preferentially integrate into nucleosome-depleted regions of the 
genome [38]. In ATAC-seq, adaptors for high-throughput sequencing are integrated into regions 
of open chromatin by hyperactive Tn5 transposase. The adaptor-tagged genomic regions can 
then be amplified and sequenced. ATAC-seq is an exciting new method for mapping open 
chromatin, as its simple two-step protocol requires less time than DNase I or FAIRE and is 
reported to perform on as few as 500 cells [37], while DNase I [30] and FAIRE [28] typically 
require at least 1 million cells.  
1.2 Chromatin in human pluripotent stem cells 
1.2.1 iPSCs differ from ESCs in subtle but potentially important ways.            
Pluripotent stem cells possess the unique capacity to indefinitely self-renew and to develop into 
all cell types in an adult body. They can potentially be used for tissue replacement after injury 
and regenerative medicine for curing disease such as Parkinson’s. The naturally occurring 
pluripotent stem cells are embryonic stem cells that are derived from an early-age embryo [39]. 
In 2006, an artificial type of pluripotent stem cells, induced pluripotent stem cells, were 
generated from mouse somatic cells by forced expression of a defined set of factors [40]. In 2007, 
human iPSCs were generated using similar strategies [41,42]. For use in regenerative medicine 
and disease research, iPSCs are proposed to have two advantages over their natural counterpart: 
they avoid the ethical concerns regarding the use of human embryos, and they can be derived in a 
patient-specific manner to avoid immune rejection after transplantation.  
iPSCs and ESCs are highly similar in many respects, including cell morphology 
[7,8,25,27,29,31,40-47], expression of pluripotency markers [7,14,26,28,40-56], histone 
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modification patterns [56-58], teratoma formation [40-42,59,60], and ability to differentiate into 
all germ layers [40-45,61-64]. Viable and fertile adult mice have been produced from mouse 
iPSCs, demonstrating their pluripotent potential [65-67]. On the other hand, studies have also 
reported genetic and epigenetic differences between iPSCs and ESCs.  
Alterations in the differentiation potential. Human iPSCs have been reported to have 
lower efficiency than ESCs in differentiation to neural [68,69] and blood lineages [70]. In 
addition, Human iPSCs have been suggested to have altered developmental potency [68,69,71-
74]; in many cases they have skewed differentiation potential towards the cell lineage of their 
cells of origin [71-73,75]. For example, iPSCs derived from human pancreatic islet beta cells 
were shown to differentiate more readily into insulin producing cells [73]. Most importantly, 
mice produced from mouse iPSCs seemed to have a higher death rate, with some displaying 
physical abnormalities [65,74]. In addition, Zhao et al. reported that in contrast to mouse ESCs, 
mouse iPSCs trigged an immune reaction after implanted in mice [76].  
Alterations in genomic DNA sequence. Compared to human ESCs, studies show that 
human iPSCs have more novel copy-number variations (CNVs) [77-79], and ten-times higher 
predicted mutation frequency [80]. 
Transcriptional activities. iPSCs and ESCs have very similar global expression [81]. 
Nonetheless, a set of genes including some developmental genes were reported to be 
differentially expressed between iPSCs and ESCs [72,81-83] . However, these genes show 
laboratory-specific expression [56,81,84], and it remains unclear whether stable patterns of 
differential gene expression are shared between different iPS cell lines. In addition, the reported 
differential gene expression between ESCs and iPSCs cannot be explained by the histone 
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modifications [56], and only partially correlate with the DNA methylation patterns at the 
promoters of these genes [72].  
Epigenetic abnormalities. Despite the global similarities of DNA methylomes and 
histone modification patterns in iPSCs and ESCs [47,48,72,85-88], aberrant methylation of CG 
dinucleotides [8,31,72,88-101] and incomplete reinstating of non-CG methylation [99-101], an 
epigenetic feature seen only in pluripotent cells, were observed. The methylation inconsistencies 
between iPSCs and ESCs are associated with epigenetic memory of somatic progenitors [71-
73,102] and de novo methylation aberrations, which appears to impact developmental potentials 
[69,71-73,102]. Residual somatic DNA methylation patterns and aberrant de novo methylations 
in iPSCs were reported to transmit to differentiated cells and contributed to transcription 
variation upon differentiation [101]. 
A few common themes regarding the genetic and epigenetic stabilities of ESCs and 
iPSCs have emerged [103]. First, these genetic and epigenetic abnormalities represent both cell-
of-origin memories [71,73,83,104] and features that are unique to iPSCs [73,81]. Some of the 
abnormalities seem to be common in several independently derived iPS cell lines [93,94,99,101], 
while others tend to be laboratory-[84,88] or technique- specific [83,105], thus are likely 
stochastic rather than functional variations. Second, the observed differences between iPSCs and 
ESCs can arise at different stages of reprogramming and subsequent culture of iPSCs [77-79]. 
Notably, some lesions, for example novel CNVs, seem to be selected against and disappear in 
higher-passage iPSCs [78], indicating they are not permanent. Third, regions prone to 
amplification, deletion or point mutation seem to be enriched in genes involved in cell-cycle 
regulation [78,80] and cancer [77,79], suggesting that some functional genomic regions may be 
more susceptible to aberrant reprogramming.  
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Taken together, these data indicate that iPSCs differ in subtle but potentially important 
ways from ESCs. Closer inspection of these differences is needed to understand how they may 
potentially affect the regulatory program that controls the pluripotent cell identity. 
1.2.2 Complete reconfiguration of chromatin structure during reprogramming is 
fundamental to the pluripotent identity of iPSCs.                                            
The pluripotent stem cell state is under the control of a transcriptional program which is 
likely implemented in the context of a particularly “open” chromatin state [106,107] that is 
unique to pluripotent stem cells. The chromatin in embryonic stem cells is at a more open state 
when compared with chromatin in somatic cells [55,108,109]. This globally open state of 
chromatin is considered important for the maintenance of pluripotency, as it allows DNA 
regulatory elements openly accessible to transcriptional regulators [106,110]. Reprogramming of 
somatic cells to pluripotent stem cells requires reconfiguration, especially re-opening, of 
chromatin. Incomplete re-opening of chromatin during reprogramming may leave an epigenetic 
memory of the original cell type, and inaccurate re-opening may result in aberrant gene 
expression. Thereby, genome-wide characterization of the chromatin structure in iPSCs in 
comparison to ESCs and parental somatic cells is essential to understand the cell identity of 
iPSCs.   
Genome-wide maps of nucleosomes with histone H3K4me3 and H3K27me3 
modifications indicate that there is little difference between ESCs and iPSCs with respect to 
these markers [56]. However, such histone mark maps do not completely reflect the global 
chromatin structure in iPSCs. Analysis of global chromatin compaction using approaches like 
DNase hypersensitivity will illustrate how completely the chromatin structure in iPSCs is 
reconfigured. 
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1.3 Functional annotation of regulatory elements in the human genome 
1.3.1 Functional annotation of the human genome requires developing high-throughput 
methods to efficiently predict and test regulatory element function on a genome-wide scale. 
DNA regulatory elements are short non-coding regions that can be bound by sequence-
specific regulatory factors that contribute to the regulation of the expression of genes. Promoter, 
enhancer, insulator and silencer are major categories of regulatory elements. The annotation of 
the human genome has suggested the existence of a large number of regulatory elements. As part 
of the effort of the Encyclopedia of DNA Elements (ENCODE) consortium, over 100,000 
putative regulatory elements are defined by open chromatin in each of the more than hundred 
human cell types and tissue samples [7,8,29,31]. The number of new sites identified has not yet 
saturated even as the number of cell lines analyzed has increased [7,8,31]. Given the variety of 
cell types present in human, the total number of regulatory elements in human genome is likely 
on the order of 106 [8,31,111]. While DNase I, FAIRE, ChIP and other methods have made 
identification of putative regulatory elements routine, those methods do not provide information 
regarding the functional activity of each element. The rapidly increased list of putative regulatory 
elements has created an urgent need for genome-scale methods that can efficiently annotate the 
functions of these putative elements.  
Regulatory elements have been discovered and characterized by gene-centric studies and 
systematic large-scale approaches. In gene-centric studies, reporter and transgenic assays are 
commonly used and rather accurate. However, these experiments are labor-intensive, and the can 
only test ~10 elements in a single experiment [112-124]. Systematic approaches include 
computationally predicting regulatory elements by transcription factor binding preference motif 
discovery [125-129] or sequence conservation [130], and experimental techniques such as DNase 
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I hypersensitive site mapping [7,8,24,25,29-31], FAIRE [7,14,27,31], and ChIP [131-135]. 
Computational predictions often exhibit high false positive and false negative rates [136,137], 
and thus the identified candidates need to be validated by experimental methods. The function of 
each individual element identified by DNase hypersensitivity of FAIRE is unknown and 
currently often inferred computationally. Data from ChIP experiments for chromatin marks that 
are specifically associated with promoters, enhancers, insulators or silencers can be used to 
directly identify these elements. For example, monomethylation of histone H3 at lysine residue 4 
(H3K4me1) [29,31,137] and transcriptional coactivator p300 [24,31] binding have proven 
predictive for enhancer activity of genomic elements. Taken together, although a large number of 
putative regulatory elements can be identified by existing large-scale approaches, compatible 
large-scale assays that can functionally test these putative elements need to be developed.  
Traditionally, regulatory elements have been functionally characterized one or a few at a 
time through serial transfection of individual reporters [112,117,118,121-124], but more recently 
DNA elements have been characterized using systematic large-scale approaches [95,97,98,138]. 
One such high-throughput functional method was designed to characterize promoter regions in 
the human genome [138]. In this study, random fragments from sheared genomic DNA were 
cloned into a GFP-based promoter reporter vector and tested for their ability to drive GFP 
reporter expression in cell culture. While they identified 858 putative promoters, this approach is 
highly inefficient as active regulatory elements in each cell type occupy less than 5% of the 
genome. Therefore most cloned fragments will not be functional. Other studies developed 
massively parallel reporter assays to test enhancer activities of either a few known human 
enhancers and a large number of their engineered variants [95,97] or a few thousand predicted 
enhancers and their variants [98]. Despite the success of those studies, it should be noted that the 
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tested enhancers were synthesized from known or predicted enhancer sequences. Such synthesis-
based approaches are costly and require exact DNA sequences of tested elements, thus it is hard 
to adapt these to the genome-wide annotation of thousand of native enhancers in a given human 
cell type of which many are unknown elements. 
1.3.2 Enhancers activate gene expression in an orientation-independent manner               
Unlike promoters that are typically immediately upstream of genes, enhancers can be 
distant-acting regulatory elements that enhance transcription levels of genes by acting on their 
promoters. They can be located upstream, downstream or within their target genes, and can 
modulate expression independent of their orientation [139,140]. They do not need to be 
particularly close to the targeted genes, and sometimes are found extremely far from their targets 
[140-142], or even on a different chromosome [143,144]. Enhancers have been shown involved 
in many developmental and disease-relevant processes [140,145-147].  
1.4 Chromosomal translocations in oncogenesis 
1.4.1 Chromosomal translocations are genetic hallmarks of most cancer cells 
Chromosomal translocations have been reported in several forms of human cancer [61-
64,148-151] and are implicated in approximately 20% of cases of cancer morbidity [150,151]. 
Translocations can lead to tumorigenesis by activating oncogenes [151-154], creating fusion 
transcripts [151,153,155-157], or disrupting normal gene activity resulting in malignant 
transformation [158,159]. Chromosomal breakpoints can be detected by cytogenetics [155,160]. 
In addition, advances in sequencing and bioinformatics are uncovering clinically relevant 
translocations and rearrangements [61-64,161].  Recently, recurrent translocations were 
discovered in >50% of prostate cancer cases [157,162], giving us new insights into the genetic 
complexity of this disease. 
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Chromosomal translocations are genetic hallmarks of most cancer cells, and some 
translocations are responsible for malignant transformation [61-64,148]. In several types of 
cancers, translocations are the causative agent of disease by producing or activating oncogenes 
responsible for malignant transformation [151,153,155-157]. On a molecular level, 
translocations require the formation of DNA double-strand breaks (DSBs) at two or more 
genomic loci, followed by the illegitimate joining of broken chromosomal ends through DNA 
repair. Depending on the chromosome breakpoints, a translocation can result in the disruption or 
misregulation of normal gene function [158,159]. These molecular rearrangements, in many 
cases, are considered to be the primary cause of various cancers [61-64]. Indeed, over the past 
few decades, clinical cytogeneticists have been able to link specific chromosome breakpoints to 
clinically defined cancers, including subtypes of leukemias, lymphomas, and sarcomas [61-
64,148-151]. Virtually all of the translocations observed in tumors have arisen through somatic 
events, so these are not inherited in families [149-151]. Translocations in some lymphomas and 
leukemias lead to the juxtaposition of promoter or enhancer elements from one gene with the 
intact coding region of another gene [151-154]. In other cases such as in Chronic myelogenous 
leukemia (CML) and many of the acute leukemias, translocations result in the recombination of 
the coding regions of two different genes [151,153,155-157]. This results in a fusion protein that 
might have a new function.  
1.4.2 The mechanisms by which translocations consistently recur between certain sites of 
the genome are largely unknown. 
Although the pathological relevance of chromosome translocations in human leukemia 
and lymphoma is well established [75,148,163], the mechanisms by which translocations 
consistently recur between certain sites of the genome are largely unknown [75,148] 
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[161,163,164]. There is increasing evidence that DSBs involved in translocations occur at non-
random sites in the genome [75,148,163]. First, the spatial arrangement of chromosomes and the 
gene fusions that result from translocations are tissue- and cell-type specific [75,148,163,165]. 
Second, breakpoints in common translocations have been cloned and tend to cluster in small 
regions of introns [75,148,163,166]. Third, studies that mapped the genome-wide landscape of 
translocations in the absence of selection found that translocations occur primarily between 
transcriptionally active regions of the genome [75,148,161,163,164]. These observations suggest 
that certain regions of the genome are more susceptible to DNA breakage and translocations; 
however, what precisely defines these sites remains unknown. There has been indication that 
local chromatin architecture may influence the recurrent translocation frequency [167,168]. 
Taken together, despite the well-documented impact of chromosomal translocations in cancer, 
the central unsolved questions in the field are what determines the sites of chromosomal 
breakage and what molecular factors influence susceptibility of DNA to breakage.  
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CHAPTER II: 
INCOMPLETE REPROGRAMMING OF DNASE HYPERSENSITIVE SITES IN 
HUMAN IPS CELLS IS ASSOCIATED WITH ALTERED REGULATION OF 
DEVELOPMENTAL GENES UPON DIFFERENTIATION 
 
2.1 OVERVIEW  
Human induced pluripotent stem cells (hiPSCs) are similar to human embryonic stem 
cells (hESCs) in many respects, but can have altered differentiation potential and DNA 
methylation patterns. A central unanswered question is how completely chromatin in hiPSCs is 
reconfigured to resemble that of blastocyst-derived hESCs, and whether any imperfections in the 
chromatin remodeling process are functionally relevant. To address these questions, we mapped 
DNaseI hypersensitive (DHS) sites using DNase-seq, which identify regions of nucleosome 
depletion and transcription factor binding, in seven samples: three human ESC lines, two human 
iPSC lines, and their two matched parental fibroblasts. Over 95% of DHS sites were shared 
between hESCs and hiPSCs, but we detected thousands of reproducible differential DHS (dDHS) 
sites. We show that dDHS sites that are not completely reprogrammed are associated with 
different levels of active and repressive chromatin marks in the parental cells prior to 
reprogramming. dDHS sites are significantly enriched for “super-enhancers” that are critical to 
hESC identity, and up to 9% of dDHS sites are themselves found in clusters, dCOREs, which 
span tens of kilobases and significantly overlap with previously identified differentially 
methylated regions (DMRs). Genes associated with dDHS sites are highly enriched for key 
transcription factors that function in early embryonic development. While RNA levels of these 
genes are typically indistinguishable in undifferentiated hESCs and hiPSCs, many of these genes 
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show differential expression in the examined hiPSCs and hESCs upon differentiation into 
mesendodermal or neuroectodermal lineages. Thus, regulatory elements susceptible to 
incomplete reprogramming in hiPSCs can be anticipated by the chromatin state in the parental 
cell, and flaws in regulatory element reprogramming foreshadow gene regulation upon hiPSC 
differentiation. While we do not claim that the exact set of dDHSs found here exists between any 
given hESC and hiPSC line, we predict that any set of dDHS sites will share the properties of the 
set we describe here.   
2.2 INTRODUCTION 
iPSCs and ESCs are similar in many respects, including cell morphology, expression of 
pluripotency markers, histone modification patterns, teratoma formation, and ability to 
differentiate into all germ layers [41-44,47,169-171]. However, there are also many differences 
[77-80,99-101], and recent studies suggest that some of these differences may be rooted in a 
failure to fully recapitulate an ESC chromatin state in iPSCs. For example, despite the global 
similarity of human iPSC and ESC DNA methylomes, aberrant methylation of CpG islands and 
incomplete restoration of methylation at non-CG mega-regions were observed in hiPSCs [99-
101]. The methylation inconsistencies between iPSCs and ESCs are associated with epigenetic 
memory of somatic progenitors [71-73,102] and de novo methylation aberrations, which appears 
to impact developmental potentials [69,71-73,102]. Residual somatic DNA methylation patterns 
and aberrant de novo methylations in iPSCs were transmitted to differentiated cells and 
contributed to transcription variation upon differentiation [31]. Adding to evidence for the 
importance of chromatin in iPSC formation, depletion of Mbd3, a core member of the NuRD 
(nucleosome remodeling and deacetylation) repressor complex results in reprogramming 
efficiencies near 100% by suppressing NuRD-mediated inhibition of downstream OCT3/4, 
	   17	  
SOX2, KLF4 and c-MYC target genes [172].  Thus, understanding the extent to which chromatin 
is correctly reconfigured at gene regulatory elements is fundamental to understanding how iPSCs 
are formed, how any underlying differences could lead to changes in transcriptional programs 
upon differentiation, and how these differences impact developmental and therapeutic potential.  
In this study we report genome-wide mapping and characterization of DNaseI 
hypersensitive (DHS) sites in human ESCs (hESCs), human iPSCs (hiPSCs), and matched 
parental fibroblast lines. DHS sites represent regions of nucleosome depletion and transcription 
factor binding to DNA, and therefore is a powerful readout of the regulatory state and potential 
of a given cell type [6,8,25]. While over 95% of DHS sites were shared between hESC and 
hiPSC lines, we identified thousands of differential DHS (dDHS) sites. Compared to completely 
reprogrammed genomic regions, DHS sites that were present in ESCs but were not fully 
reprogrammed to an open state in iPSCs displayed lower levels of active chromatin marks and 
higher levels of repressive marks in the parental cell line, indicating a likely mechanism behind 
sub-optimal reprogramming.  Differential DHS (dDHS) sites such as these were often found near 
each other, forming dCOREs (differential Clusters of Open Regulatory Elements), and also 
occurred preferentially in “super-enhancers”, which were recently identified in hESCs and 
shown to be important for ES cell identity and function [31]. Clusters of dDHS sites were also 
significantly enriched around key developmental genes, including SOX, ZIC, PAX, HOX, FOX, 
and HMX gene family members.  Interestingly, the transcriptional output of those genes was 
indistinguishable between undifferentiated hESCs and hiPSCs, but after differentiation towards 
mesendodermal or neurectodermal lineages, many such genes displayed differential expression 
profiles. Our study shows that chromatin sites in somatic cells that are resistant to 
reprogramming have characteristic chromatin features, and that these sites of incomplete 
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reprogramming in iPSCs foreshadow differences in regulation of gene expression upon 
differentiation. DNase-seq screening of undifferentiated hiPSC lines may identify those that are 
unable to efficiently differentiate into specific somatic cell lineages and reveal new insight into 
the genetic and epigenetic mechanisms that regulate early human development. 
2.3 RESULTS 
2.3.1 Human ESCs and iPSCs have very similar accessible chromatin profiles 
To assess the completeness of chromatin reconfiguration during the reprogramming of 
human somatic cells, we examined the landscape of DNaseI hypersensitive (DHS) sites across 
the genome in seven samples: three human embryonic stem cell (hESC) lines (H1, H7, and H9), 
two human induced pluripotent stem cell (hiPSC) lines, and their two matched parental 
fibroblasts (Figure 2.1.A-C). To ensure reproducibility, three biological replicates were analyzed 
from each line (two replicates of H1; see Methods). DHS sites mark most transcription factor 
binding sites and overall chromatin accessibility [6,8,25], and therefore provide a powerful 
indicator of global chromatin reprogramming. We also measured RNA levels in all samples 
using Affymetrix human exon arrays. 
As expected, the accessible chromatin profiles of hiPSCs closely resembled those of 
hESCs, but were distinct from their parental fibroblasts (Figure 2.1.B). For example, three DHS 
sites surrounding NANOG, a key transcriptional regulator of pluripotency, were shared only by 
hESC and hiPSC lines, while a separate DHS site near NANOG was present only in fibroblasts 
(Figure 2.1.C). Among the 79,190 DHS sites that were common to all hiPSC lines and the 
53,250 DHS sites that were common to all hESC lines, 48,870 sites were shared between them 
(Figure 2.1.B). Of these, 29,063 DHS sites were also present in parental fibroblasts, leaving 
19,807 DHS sites that were unique to hESCs and hiPSCs. Using the same criteria, only 8,220 
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sites were shared between hiPSCs and their fibroblast progenitors and were not found in hESCs. 
This indicates that the chromatin of hiPSCs is far more similar to hESCs than to their cell type of 
origin.  
We also examined similarity among the samples by analyzing the DHS signal intensity 
using principle component analysis (PCA) (Figure 2.1.D) and hierarchical clustering (Figure 
2.1.E). Similar analyses were performed using RNA expression data (Supplemental Figure 
2.1.A-B). In each analysis, the hESC lines grouped together with the hiPSC lines in both 
chromatin and gene expression space and were well separated from the parental fibroblast lines. 
This analysis confirmed that the genome-wide chromatin landscapes of hiPSCs are more similar 
to those of hESCs, and both are comparatively different from the landscapes of the parental 
fibroblast cells. This general similarity in DHS sites between hiPSCs and hESCs is consistent 
with what was previously observed using alternate methods such as DNA methylation and 
histone profiling [88,99,101,173]. 
2.3.2 Approximately 4% of DHS sites are differentially accessible between hESCs and 
hiPSCs 
Differentially methylated regions exist between ES and iPS cells [99,101]. Some of these 
regions reflect methylation marks that were not erased from somatic cells during the 
reprogramming process (called “memory” marks), while others were de novo methylation events 
specific to iPSCs.  
To identify differential DHS sites between hESCs and hiPSCs, we first identified DHS sites 
present in all (intersection) samples from one cell type but that were missing in any (union) of  
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Figure 2.1. Experiment description and data overview. A) Experimental design. DNase-seq 
and expression analysis was performed on three human ESC lines, two skin fibroblast lines, and 
two iPS lines that were derived from the skin fibroblasts. Human iPS cell lines were generated 
with pMX-based retroviral vectors carrying OCT4, SOX2, KLF4, and MYC [41]. Three 
biological replicates were analyzed for each line.  B) Diagram showing number of DHS sites that 
were shared between human ES, fibroblast, and iPS cell lines. Note that hiPSC and hESC DHS 
sites are highly similar, and the presence of memory DHS sites shared between ESC and 
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fibroblasts. C) Representative DNase-seq data (left) from all three cell types shows data is of 
high quality.  Region surrounding NANOG locus (right) shows DHS sites that are similar 
between hiPSC and hESC lines (orange boxes), and were different to DHS sites found only in 
fibroblast lines (gray box).  Biological replicates (R1, R2, and R3) were shown for each cell line.  
A DHS sites downstream of NANOG was detected in all cell lines. The y-axis for each DNase-
seq dataset was fixed at a constant normalized read depth. D-E) Replicates of hiPSC lines 
clustered with replicates of hESC lines and were separated from their parental fibroblast lines in 
chromatin space by both PCA clustering (D) and hierarchical clustering (E). (See also Figure S1) 
 
the other two cell types (Supplemental Figure 2.2). We chose this approach over our initial 
comparisons (described above) to be more conservative and to exclude differential sites that 
might arise due to thresholding artifacts. For DHS sites that are present in both hESCs and 
hiPSCs, we also identified those with statistically different signal intensities using the R package 
edgeR [172,174,175] (see Methods). Considering all 158,393 DHS sites that represent the union 
set of DHS from hESCs and hiPSCs, together these methods identified 5,799 differential DHS 
(dDHS) sites (~4%). These dDHS were grouped into 3 categories (Figure 2.2A): (1) hESC 
dDHS sites representing 2,600 DHS sites that were more open in hESCs than in hiPSCs and not 
open in the parental fibroblast lines (Figure 2.2B), (2) hiPSC dDHS sites representing 2,221 
DHS sites that were more open in hiPSCs than in hESCs and not open in the parental fibroblast 
lines (Figure 2.2C), and (3) Memory dDHS sites representing 978 DHS sites that were shared by 
all hiPSC lines and all fibroblast lines but not present in any of the hESC lines (Figure 2.2D) 
(see Table S1 for the complete list).  Given the variability in DNA methylation recently detected 
across many hiPSCs [88], we do not expect that the dDHS sites identified with the particular 
lines used in our study represent a universal “signature” that is shared among all hiPSCs and 
hESCs. Analysis of additional lines will likely identify a different but partially overlapping set of 
dDHS sites, which we predict will share the same features as the set we describe below for the 
reasons explained below.   
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Figure 2.2 Approximately 4% DHS sites are differentially DHS (dDHS) between hESCs 
and hiPSCs.  A) Genome-wide analysis identifies 5,799 hESC, hiPSC, and memory dDHS sites. 
Specifically, we identified 2,600 hESC dDHS sites that were identified only hESCs or were more 
open in hESCs, 2,221 hiPSC dDHS sites that were identified only in hiPSCs or more open in 
hiPSCs, and 978 memory dDHS sties that were open in both iPSCs and their parental fibroblasts 
but not in hESCs. B) A cluster of hESC dDHS sites (gray box) at PTPRN2 locus. C) Example of 
hiPSC dDHS site upstream of GLYATL1 gene. D) Example of memory dDHS site at TSS of 
TRIM4. (See also Supplemental Figure 2.2)  
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2.3.3 dDHS sites often map in clusters  
We noticed a large cluster of dDHS sites at the PTPRN2 gene locus that span a 1Mb 
genomic region (Figure 2.2B). In this region, 69 of the 72 DHS sites were identified as hESC 
dDHS sites, while none of these were hiPSC dDHS sites. It has been previously suggested that 
clusters of dDHS in close proximity might act together to influence gene expression or other 
chromosomal functions [7,27]. To systematically determine whether dDHS sites tended to 
cluster together in the genome, we plotted the location of all dDHS sites on individual 
chromosomes and observed that clusters of dDHS sites grouped together in a non-random 
manner (Supplemental Figure 2.3A). For example, we found large domains of similarly defined 
hESC dDHS sites (Figure 2.3A, red arrow), hiPSC dDHS sites (Figure 2.3A, green arrow), and 
memory dDHS sites (Figure 2.3A, blue arrow).  
To provide a more detailed characterization of dDHS domains, we next analyzed the 
distance between each pair of dDHS sites within each of the three categories. A significant 
percentage of both hESC dDHS sites (8.5%) and hiPSC dDHS sites (5.9%) were within 10kb of 
another hESC dDHS site or hiPSC dDHS site, respectively (Figure 2.3B). In contrast, we found 
very few pairs of memory dDHS sites (0.3%) within 10kb of each other. Permutated dDHS sites 
rarely (< 0.3%) clustered together (see Methods).  We thereby defined a dCORE (differential 
Clusters of Open Regulatory Elements) as a stretch of dDHS sites in which each dDHS site was 
within 10kb of another dDHS site of the same type. In this manner, 63 hESC dCOREs, 37 hiPSC 
dCOREs, and 1 memory dCORE were identified (Figure 2.3C). In contrast, only 2 clusters were 
identified when considering sets of permutated dDHS sites (see Methods). dCOREs were 
detected throughout the genome (Supplemental Figure 2.3B), and the sizes ranged up to 63kb, 
with the largest hESC and hiPSC dCOREs consisting of 9 dDHS sites each. Given the large 
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number of hESC and hiPSC dCOREs relative to clusters of permuted dDHSs sites, these 
dCOREs likely represent functionally linked differences in chromatin states between the two cell 
types.   
 
 
Figure 2.3. dDHS sites occurred in clusters. A) Distribution of hESC, hiPSC, and memory 
dDHS sites on a representative locus on chromosome 8. Note that dDHS sites appear to cluster 
by dDHS type. B) Distribution of dDHS sites for each chromosome (top) and relative numbers of 
hESC dDHS vs. hiPSC dDHS (bottom). C) A higher than expected proportion of hESC dDHS 
sites and hiPSC dDHS sites cluster were within 10kb of their closest hESC dDHS site or hiPSC 
dDHS sites, respectively.  Most memory dDHS sites did not cluster.  D) Clusters of dDHS of the 
same type define dCOREs. Each dCORE consists of at least three dDHS sites of the same type 
that are within 10kb of another dDHS site. (See also Supplemental Figure 2.3) 
 
To gain insight into the biological significance of dCOREs, we compared them to 
previously identified “hotspots” of differentially methylated CG (CG-DMRs) and megabase-
scale non-CG regions (non-CG mega-DMRs) that exhibited aberrant DNA methylation patterns 
in hiPSCs relative to hESCs [99,101]. Lister et al. identified 1,175 CG-DMRs that cover 
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approximately 1.7 MB, and 25 non-CG mega-DMRs (after liftover) that cover approximately 
29MB [99]. 20 (32%) of 63 hESC dCOREs and 8 (11%) of 72 hiPSC dCOREs overlapped with 
CG-DMRs, and 9 (14%) of hESC dCOREs overlapped with non-CG mega-DMRs. The overlaps 
were statistically significant (p-values < 2.2e-16) given the overall coverage of CG-DMRs and 
non-CG mega-DMRs. Notably, the PTPRN2 locus described above (Figure 2.2B) contained a 
non-CG mega-DMR [99], and was differentially methylated at its nearby CpGs in 9 of 17 hiPSC 
lines relative to 7 hESC lines analyzed by Ruiz et al. [101]. In total, 7 hESC lines were used in 
the two DNA methylation studies, and 22 individual hiPSC lines derived from 9 distinct parental 
cell lines with varied reprogramming efficiencies using 3 different protocols. Therefore, we 
believe that overlapped regions between DMRs highlighted in the DNA methylation studies and 
dCOREs identified in this study are likely features common to hiPSC lines and are biological 
significant. It suggests that, despite the variation in the epigenetic landscape among hiPSC lines, 
incomplete reconfiguration of the epigenetic state is shared by hiPSCs at a set of megabase-sized 
genomic regions such as dCOREs. As stated above, we predict that analysis of open chromatin in 
additional hiPSC lines will identify a different but partially overlapping set of dDHS sites, with 
the overlapping sites frequent in those shared megabase-scale regions. 
2.3.4 dDHS sites occur more often than expected in super-enhancers 
Large genomic domains containing clusters of transcriptional enhancers termed “super-
enhancers” have been recently characterized in various human cell types [176]. Super-enhancers 
are suggested to drive cell type-specific gene expression patterns and play key roles in the 
control of cell identity [176-178]. ESC super-enhancers are bound by Oct4, Sox2, Nanog, and 
mediator, and these regions stimulate higher transcriptional activity than typical enhancers 
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[176,177]. To explore whether dDHS sites overlapped super-enhancers, we examined the 684 
super-enhancers identified in H1 hESCs [176].  
Of all 158,393 DHS sites identified in hESCs and hiPSCs, 1,955 (1.2%) overlapped with 
655 (95%) H1 super-enhancers. Using this as our baseline for the expected proportion of overlap, 
we found that a significantly higher proportion of hESC dDHS sites (n=75, 2.8%; p = 2.33e-10) 
overlapped with H1 super enhancers (n=65, 9.5% of all H1 super-enhancers). A higher 
proportion of hiPSC dDHS sites (n=42, 1.9%; p-value 0.0058) also overlapped with H1 ESC 
super-enhancers (n=32, 4.7%).  While these numbers may seem small on an absolute scale, this 
is to be expected given the small number and genomic coverage of super enhancers. In fact, these 
overlapping dDHS/super-enhancer sites have outsized significance not only statistically but 
biologically, occurring near key developmental genes such as SOX2, SOX2-OT (Supplemental 
Figure 2.6), ZIC2, ZIC5 (Supplemental Figure 2.7), SOX11, and SOX21 (Supplemental 
Figure 2.7). Furthermore, 6 of 63 ESC dCOREs (9.5%) and 2 of 37 iPSC dCOREs (5.4%) 
overlapped with H1 super-enhancers.  In contrast, fewer than expected memory dDHS sites (n=2, 
0.2%; p-value 7.20e-05) overlapped with H1 super-enhancers (n=2, 0.3%).   
We also compared dDHS sites to super-enhancers identified in fibroblast lines NHDF-
Ad, NHLF, and IMR90 [176]. Approximately 5% of memory dDHS sites overlapped super-
enhancers for all three cell types, which was a significant enrichment (p-values < 3e-07) over 
that of all hESC and hiPSC DHS sites (~1.2%). The single memory dCORE did not overlap with 
any H1 super-enhancers, but did overlap with super-enhancers identified in HMEC (human 
mammary epithelial cells) and 15 other differentiated human cell and tissue types. Together our 
results show that compared to all DHS sites, ESC dDHS sites are significantly enriched for H1 
super-enhancers that are crucial for hESC identity.  In addition, memory dDHS sites were found 
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less often than expected in H1 super-enhancers, but more often than expected in fibroblast super-
enhancers.   
2.3.5 hESC, hiPSC, and memory dDHS sites display differences in basal chromatin state 
prior to reprogramming  
We asked why chromatin remodeling failed or was incomplete at some genomic regions, 
while throughout most of the genome chromatin accessibility in hiPSCs was indistinguishable 
from hESCs. To test whether specific genomic features are associated with impaired 
reprogramming, we compared the intensity of histone modifications and transcription factor 
binding at dDHS sites where reconfiguration was incomplete and genomic regions that were 
successfully reprogrammed. Since reprogramming was initiated from the fibroblast lineage, we 
used ENCODE ChIP-seq data on the skin fibroblast cell line NHDF-Ad and the primary 
fibroblast cell line AG04450 [31] to characterize the chromatin status at different types of dDHS 
sites in fibroblast cells prior to reprogramming. We examined histone modifications or variants 
associated with active chromatin (H3K9ac, H3K27ac, H3K4me1, H3K4me2, H3K4me3, 
H3K36me3, H3K79me2, H4K20me1, and H2A.Z), repressed chromatin (H3K9me3, 
H3K27me3, and the poly-comb complex protein EZH2), and the binding of insulator protein 
CTCF. We compared ChIP signals in fibroblast cells at hESC dDHS sites (Figure 2.4A; 
Supplemental Figure 2.4A), hiPSC dDHS sites (Figure 2.4B; Supplemental Figure 2.4B), and 
memory dDHS sites (Figure 2.4C; Supplemental Figure 2.4C) to their relevant control regions 
(see Methods).  
Compared to DHS sites that were successfully reprogrammed, hESC dDHS sites had 
decreased levels of the active chromatin marks H3K9ac (p-value 0.001), H3K27ac (p-value < 
0.001), H3K4me2 (p-value 0.002), H3K4me3 (p-value 0.008), and H2A.Z (p-value < 0.001), and 
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increased levels of all repressive marks analyzed (p-value < 0.02) (Figure 2.4A; Supplemental 
Figure 2.4A). This indicates that hESC dDHS sites that failed to reprogram were in a more 
closed chromatin state in fibroblasts, possibly resulting in less accessibility to transcription 
factors or chromatin remodelers that are required to reprogram the chromatin state of fibroblasts. 
The trend was consistent for ChIP-seq data from both the NHDF-Ad and primary AG04450 
fibroblast cell lines (Supplemental Figure 2.4A). This observation is consistent with the 
previous report of OSKM-Differentially Bound Regions (OSKM-DBRs), which are refractory to 
binding of pioneer reprogramming factors Oct4, Sox2, Klf4, and c-Myc (O, S, K, and M) [179]. 
Soufi et al. showed that H3K9me3 is the dominant chromatin feature at these OSKM-DBRs and 
is an impediment to initial OSKM Binding. Indeed, 218 (8%) of 2,600 hESC dDHS sites were 
found in OSKM-DBRs.  
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Figure 2.4 dDHS regions show differences in local chromatin environment in differentiated 
somatic cells prior to reprogramming compared to controls.  ChIP-seq data from NHDF-Ad 
fibroblast cell line was compared to regions identified as hESC dDHS (A), hiPSC dDHS (B) and 
memory dDHS (C).  For each panel, CTCF is shown on the left, followed by active histone 
marks in the middle, and repressive marks to the right. A) hESC dDHS (blue line) were 
compared to control DHS sites (black line) that were present in hiPSCs and hESCs, but not 
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fibroblasts (see gray inset for pictorial representation).  Direction of significant enrichment is 
shown by red (higher) and green (lower) arrows. Asterisks indicate significant p-values based on 
random permutation analysis (* p-value < 0.05; ** p-value < 0.005).  Black arrows indicate 
trends that did not reach significance. Relative to control sites, hESC dDHS sites had lower 
levels of active histone marks and higher level of repressive histone marks. B) hiPSC dDHS 
(blue line) were compared to control DHS sites (black line) that were identified in a previous 
study but are not present in any of the three cell types.  Relative to control sites, hiPSC dDHS 
sites had higher levels of both active histone marks and repressive histone marks. C) Memory 
dDHS (blue line) were compared to control DHS sites (black line) that were only present in 
fibroblasts.  Relative to control, memory dDHS sites had higher levels of active histone marks. 
(See also Supplemental Figure 2.4) 
 
To our surprise, hiPSC dDHS sites displayed higher levels of active H3K4me2 chromatin 
marks (p-value < 0.01), repressive EZH2 and H3K27me3 chromatin marks (p-values < 0.001), 
and insulator protein CTCF (p-value < 0.001) in ChIP-seq data from NHDF-Ad fibroblast cells 
(Figure 2.4B; Supplemental Figure 2.4B). Higher levels of both active chromatin marks 
(H3K27ac and H3K4me3) and repressive chromatin marks (H3K27me3) were also observed in 
AG04450 ChIP-seq data (Supplemental Figure 2.4B). For this comparison, hiPSC dDHS sites 
were measured against genomic regions previously identified as a DHS site in at least one of 
>100 samples from various cell types [180] but that did not represent a DHS site in hESCs, 
hiPSCs, and fibroblasts (see Methods). In other words, the hiPSC dDHS sites, which were 
closed in somatic cells and then inappropriately opened during reprogramming, had higher levels 
of either repressive or active histone marks in the starting somatic cell. This conclusion was 
made in comparison to regions of closed chromatin in somatic cells that remained properly 
closed during reprogramming. The presence of either chromatin state in fibroblasts may make 
these regions more amenable to chromatin remodeling than other regions of closed chromatin.  
Compared to fibroblast DHS sites that were successfully closed in iPSCs, memory dDHS 
sites had higher levels of H2A.Z (p-value < 0.001) and H3K4me2 (p-value 0.03) active 
chromatin marks, higher levels of insulator protein CTCF (p-value < 0.001), and slightly higher 
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level of EZH2 (p-value 0.02) in ChIP-seq data from NHDF-Ad fibroblast cells  (Figure 2.C; 
Supplemental Figure 2.4C).  Similar trends were observed in ChIP-seq data from the primary 
fibroblast cell line (Supplemental Figure 2.4C). This indicates that compared to DHS sites that 
closed during reprogramming, the memory dDHS sites that were more resistant to being 
reconfigured to a closed state harbored more active chromatin marks prior to reprogramming. 
2.3.6 hESC and hiPSC dDHS sites contain KLF4 motifs, and most memory dDHS sites 
contain an AP-1 motif 
To test whether the identified dDHS sites contained unique sequence features we 
performed de novo motif analysis on each class of dDHS sites.  The motif for KLF4 was detected 
in both hESC dDHS sites and hiPSC dDHS sites (Supplemental Figure 2.5A), indicating a 
possible role for one of the four reprogramming factors in over- or under-reprogramming certain 
regulatory elements. In addition, the DNA motif for AP-1 was significantly enriched in memory 
dDHS sites (Supplemental Figure 2.5A). AP-1 is a transcription activator complex composed of 
Fos and Jun family members, and has been shown to function as a pioneer factor that facilitates 
access to chromatin [181]. Approximately 70% of all memory sites contained an AP-1 motif.  In 
addition, 55% of FOSL2 and 44% of JUND ChIP-seq sites overlapped with memory sites (see 
Methods), which were significantly higher than the < 10% overlap of FOSL2 and JUND ChIP-
seq sites with hESC dDHS sites and hiPSC dDHS sites (p-value < e-100). The enrichment of the 
AP-1 motifs and binding sites in memory dDHS suggests that AP-1 may contribute to the 
persistence of open chromatin at those loci.  
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2.3.7 Clusters of differential DNase Hypersensitive sites are connected to loci encoding key 
developmental transcription factors 
The observation that dDHS sites tended to occur in clusters suggests that they might 
cooperatively regulate the transcription of a nearby gene. Only a small fraction (7%) of dDHS 
sites was at or near gene transcription start sites (TSS), indicating most dDHS sites represent 
distal regulatory elements such as enhancers (Supplemental Figure 2.5B). To connect all DHS 
and dDHS sites to their target genes, we used a previously developed methodology based on 
correlation between the DHS site signal intensity and the expression level of a gene across 112 
human cell line and tissue types, which incorporates data from hESC and hiPSC lines [180]. 
Using this connection matrix, we found 45,143 of the 158,393 DHS sites from either hESCs or 
hiPSCs were connected to 24,529 genes (out of 36,638 total coding and non-coding genes on the 
Affymetrix exon array), representing a total of 96,383 connections (some individual DHS sites 
were connected to multiple genes, and some genes were connected to multiple DHS sites). 
Among the connected DHS sites, 2,483 (5.5%) were dDHS sites, which were involved in 5,734 
connections. The median connectivity of dDHS sites was 2 genes, which was the same as that of 
other hESCs or hiPSC DHS sites.  
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Figure 2.5. dDHS sites clustered around developmental genes.  A) List of the top 100 genes 
that were most connected to hESC, hiPSC, or memory dDHS sites.  Genes were divided by 
different gene ontology categories and rank ordering for each gene is indicated in parentheses. B) 
hESC dDHS sites clustered around developmental genes. Genes highlighted in red were also 
connected to hESC dCOREs. C) hiPSC dDHS sites clustered around a non-overlapping set of 
developmental genes. Genes highlighted in red were also connected to hiPSC dCOREs. (See also 
Supplemental Figure 2.5) 
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We sought to identify genes that were connected to more dDHS sites than expected and 
thus were potentially differentially regulated in hESCs and hiPSCs. For each gene we counted 
the number of connected DHS and dDHS sites. To determine enrichment of dDHS connections 
compared to the background frequency, we calculated FDR-adjusted p-values using the exact 
binomial test (see Methods). All genes were ranked by their FDR-adjusted p-values, and smaller 
p-values indicate greater enrichment of dDHS sites connected to a gene. The top 100 ranked 
genes based on these p-values are listed in Figure 2.5A (see Table S3 for the complete list).  
We manually grouped the top 100 genes that were enriched for dDHS site connections 
into six general categories based on GO term annotations (see Methods, Figure 2.5A). The most 
prominent feature of this list was 25 genes that were transcription factors and other key 
regulators of early embryonic development. This includes SOX2, one of the four reprogramming 
factors that is also critical in early neural differentiation, and PAX6, a master transcription factor 
that is important for the development of the eye, nose, central nervous system and pancreas. 
Additional developmental genes represented in the top 100 that were enriched for dDHS sites 
were HOXA, ZIC, FOXA and HMX gene family members (Supplemental Figure 2.6, 
Supplemental Figure 2.7).  
2.3.8 hESC and hiPSC dDHS sites are connected to distinct sets of key developmental genes 
Each of the top 100 connected genes appeared to be enriched for either hESC dDHS sites 
or hiPSC dDHS sites but not both (Fig. 5B-C). For example, of the 9 dDHS sites mapped in the 
~110 kb HOXA gene locus, all were comprised of only hESC dDHS sites. Similar enrichment 
for hESC dDHS was found at SOX2, ZIC2 and ZIC5 (Fig. 5B), while SOX1, SOX5 and ZIC3 
genes were enriched for hiPSC dDHS sites (Fig. 5C). To test whether hESC or hiPSC dDHS 
sites were both ever observed in the same gene, we repeated the exact binomial test described 
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above on hESC, hiPSC, and memory dDHS sites separately. We found 78 genes enriched for 
hESC dDHS sites, 193 genes enriched for hiPSC dDHS sites, and 344 genes enriched for dDHS 
memory sites (FDR-adjusted p < 0.05) (see Table S4 for the complete list). Only 2 genes were 
held in common between the hESC and hiPSC enriched gene sets, indicating that each class of 
dDHS generally associates with a distinct set of genes. Similarly, hESC dCOREs and hiPSC 
dCOREs were connected to different sets of developmental genes (Fig. S3C-F; see Table S5 for 
the complete list), including several of the genes enriched for hESC dDHS and hiPSC dDHS 
sites (Fig. 5B-C, highlighted in red).  Consistent with this, each class of dDHS site were 
functionally distinct (Table S6). hESC dDHS-associated genes were strongly enriched for GO 
categories related to development. In contrast, genes enriched for hiPSC and memory dDHS sites 
were not significantly associated with specific GO terms. Thus, DNase sites that are open in 
ESCs but not iPSCs tend to be connected to genes with developmental functions, while DNase 
sites that are open only iPSCs but not ESCs are not functionally coherent.   
2.3.9 Genes highly connected to dDHS sites are differentially regulated upon differentiation 
Previous studies have shown that RNA transcript levels in hESCs and hiPSCs are very 
similar [41,88]. We also found that overall transcript abundance in hESCs and hiPSCs was 
highly concordant based on our exon array data (R = 0.98, Pearson correlation). In addition, all 
494 genes that were highly connected to any type of dDHS site had less than two-fold 
differences in expression between hESCs and hiPSCs (Figure 2.6A). This could suggest that the 
dDHS sites between hESCs and hiPSCs do not have major functional consequences. However, 
we noticed that developmental genes located near dDHS sites were not appreciably expressed in 
either pluripotent cell type. Therefore, we wondered whether functional consequences of dDHS 
sites are manifested only after the cells are induced to differentiate into somatic cell derivatives.  
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We analyzed published expression data from the same hESC and hiPSC lines used in our 
DHS analysis that were differentiated into mesendodermal and neurectodermal lineages [182]. 
For hESCs, we identified 2,084 and 6,509 genes that were significantly up- or down-regulated 
during ectodermal or mesendodermal differentiation (see Methods). We then divided these 
genes into four categories: hESC dDHS site enriched genes; hiPSC dDHS site enriched genes; 
memory dDHS site enriched genes; and genes not enriched for dDHS sites (see Figure 2.2A). 
We found 20, 22, 23, and 2,019 genes in each group, respectively, upon neurectodermal 
differentiation, and 42, 69, 72, and 6,326 genes, respectively, upon mesendodermal 
differentiation. 
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Figure 2.6. Incomplete chromatin reconfiguration may foreshadow altered gene regulation 
upon differentiation.  A) Global expression is highly similar between hiPSC and hESC lines 
(R=0.983). The top 100 genes that were most connected to dDHS sites are indicated as involved 
in development (red) and other gene ontology categories (yellow). B) Differentially expressed 
genes were identified in hESCs during in vitro differention into neuroectoderm (top) and 
mesendoderm (bottom).  For differentially expressed genes surrounding hESC dDHS sites 
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(n=20), these genes displayed significantly lower fold changes in gene expression during hiPSC 
differentiation compared to hESC differentiation (red box plots, p-values indicated).  
Differentially expressed genes around hiPSC dDHS (green boxes), memory dDHS (blue boxes), 
or non-dDHS sites (white boxes) do not display differences in fold expression changes. C) 
Comparison similar as (B) but based on genes that are differentially expressed during hiPSCs 
differentiation into neuroectoderm (top) and mesendoderm (bottom).  Genes enriched for hiPSC 
dDHS (green boxes) and memory dDHS (blue boxes) were improperly regulated in hiPSCs 
during neurectodermal differentiation, but not mesendodermal differentiation. (See also Figure 
S6, Figure S7) 
 
To test whether genes connected to hESC dDHS (sites only open in ESCs) were 
differentially regulated during hiPSCs differentiation, we compared the fold change in RNA 
levels of these genes during mesendodermal and neurectodermal differentiation between hESCs 
and hiPSCs (Figure 2.6B). We found that genes enriched for hESC dDHS (sites open only in 
hESCs not hiPSCs) had significantly lower fold-changes in hiPSCs compared to hESCs during 
both neurectodermal (p-value 0.0133) and mesendodermal (p-value 0.0019) differentiation (red 
bars, Figure 2.6B and examples in Supplemental Figure 2.7A). Genes connected to hiPSC 
dDHS sites, memory dDHS sites, and those not significantly connected to dDHS sites had 
similar changes in RNA abundance in hiPSCs and hESCs. 
Conversely, we tested whether genes connected to hiPSC dDHS sites (sites open only in 
hiPSCs) would be upregulated during differentiation of hiPSCs (Figure 2.6C). We identified 
1,130 and 4,151 differentially expressed genes upon neurectodermal or mesendodermal 
differentiation in hiPSCs (Figure 2.6C). As above, we divided genes into four categories: hESC 
dDHS site enriched genes; hiPSC dDHS site enriched genes; memory dDHS site enriched genes; 
and genes without enrichment for dDHS sites (see Figure 2.2A). We found 8, 4, 13, and 1,105 
genes in each group, respectively, upon neurectodermal differentiation, and 20, 46, 42, and 4,043 
genes, respectively, upon mesendodermal differentiation. We calculated gene expression fold 
change in each group upon differentiation in hESCs and hiPSCs (Figure 2.6C). Despite the 
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small numbers per group, as predicted by our hypothesis, genes enriched for hiPSC dDHS sites 
and memory dDHS sites displayed a greater fold change in expression during neurectodermal 
differentiation in hiPSCs compared to hESCs (Figure 2.6C, green and blue bars and examples 
in Supplemental Figure 2.7B). In contrast, genes associated with hESC dDHS sites and genes 
without dDHS enrichment showed similar changes in transcription levels in hiPSCs and hESCs. 
Interestingly, during mesendodermal differentiation, transcript level changes were similar in 
hESCs and hiPSCs for all groups of genes, including those enriched for hiPSC dDHS or memory 
dDHS sites (Figure 2.6C, bottom).  This suggests that hiPSC dDHS sites may influence 
regulation during differentiation into some somatic lineages, but not others. 
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Figure 2.7.  Incompletely reprogrammed DHS sites around GABR locus foreshadows 
altered expression after in vitro differentiation.  A) Locus on chromosome 4 
(chr4:46,039,200-47,216,540) that harbors DHS sites which are specifically missing in hiPSC 
line NIHi7 at promoters of GABRA2, GABRA4, and GABRB1 genes.  B) Expression data 
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showing that these genes are not upregulated in NIHi7 (red box) after mesendodermal 
differentiation.  Other pluripotent cell lines differentiated into mesendodermal lineage express 
higher levels of these genes. C) Expression data showing no change in expression for these genes 
in any hiPSC or hESC after differentiation towards neuroectoderm. D) Schematic diagram 
depicting hESC dDHS sites (gray triangles) having a functional impact in individual hiPSC lines 
on gene expression of key developmental genes only after differentiation.  While this diagram 
indicates a deficiency in a single cell lineage (gray box), analysis of additional cell lineages 
(dotted line) will be needed to understand the full impact of dDHS sites. 
 
In addition to differentiation lineage-specific differences between hiPSCs and hESCs, we 
also detected lineage-specific differences between the two hiPSC lines.  For example, differential 
chromatin accessibility was observed in only one of the hiPSC lines (NIHi7) surrounding the 
GABR locus. DHS sites were present at the TSSs of GABRA2, GABRA4, and GABRB1 in all 
hESC lines and hiPSC line NIHi11, but were missing in hiPSC line NIHi7 (Figure 2.7A). 
During mesendodermal differentiation, the expression of these three genes were up-regulated in 
the hESC cells lines and NIHi11, but was not changed in NIHi7 (Figure 2.7B). In contrast, 
during neurectodermal differentiation these genes exhibited no change in expression for any of 
the cell lines (Figure 2.7C). Thus, genes lacking appropriate DHS sites in specific hiPSC lines 
exhibit altered gene regulation that are only detected upon differentiation into certain lineages. 
This supports our hypothesis that a lack of DHS sites at a given locus in all or a subset of 
individual hiPSCs can foreshadow improper gene regulation during in vitro differentiation 
(Figure 2.7D). 
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2.4 DISCUSSION 
Here we report a genome-wide comparison of chromatin accessibility between human 
ESCs, fibroblasts, and iPSCs derived from these fibroblasts. While DHS sites of reprogrammed 
hiPSCs are remarkably similar to hESCs, approximately 4% of DHS sites exhibited differential 
accessibility.  These dDHS sites are associated with genes that include key developmental factors. 
Despite the high transcriptional concordance in undifferentiated cells, we observed that some of 
these dDHS-enriched developmental genes were inappropriately regulated during differentiation 
(see Figure 2.7D).  Our data are consistent with the hypothesis that chromatin landscape 
required for gene regulation in somatic lineages pre-exists in undifferentiated pluripotent stem 
cells [183]. 
In human iPSC studies, especially those for their potential usage in regenerative 
medicine, it is critical to screen for and use fully reprogrammed iPSC clones. However, typically 
only a small fraction (less than 1%) [184] of transfected cells turn into fully reprogrammed iPSC 
clones. To date, immunohistochemistry, transcription profiling, and DNA methylation assays at 
promoters of key pluripotent markers are routinely used for primary validation and 
characterization of iPSC lines. Our study shows that the different chromatin architecture in 
iPSCs may have little impact on gene transcription at pluripotent states but can significantly 
influence the regulation of gene transcription including some key developmental factors upon 
differentiation. We do not expect that every hiPSC and/or hESC line will have the exact same set 
of “signature” dDHS sites. Instead, each pluripotent line will likely have its own set of chromatin 
differences that share characteristics similar to the ones described here. Therefore, evaluation of 
open chromatin configurations may be useful for identification of iPSCs with specific 
differentiation potentials. 
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2.4.1 Differential DNase sites occur in clusters, an arrangement of regulatory elements seen 
at key lineage-specific genes across cell types 
We found 9% and 6% of hESC and hiPSC dDHS sites, respectively, in clusters 
(“dCOREs”) that span tens of kilobases.  Similar observations of clustered regulatory elements 
have been reported in pancreatic islets [27]. More recently, blocks of active regulatory element 
super-enhancers that were typically >10kb in length were described in mouse and human ESCs, 
as well as in 86 diverse human cell types [176-178]. Approximately 10% of ESC dCOREs 
overlapped with super-enhancers identified in H1 hESCs. Therefore dCOREs likely represent a 
regulatory paradigm that exists across different cell types and is specifically associated with 
genes that control and define cell identity. The presence of dCOREs suggests that 
reprogramming of chromatin architecture at individual elements within these clusters may occur 
in a coordinated fashion. In addition, given the cell type-specific nature of super-enhancers, we 
speculate that the dCOREs in different hiPSC lines may vary depending on their cell types of 
origin. Future studies that characterize dDHSs and dCOREs between iPSC lines generated from 
different cell types can facilitate the understanding of the process and mechanism of chromatin 
reprogramming and potentially help improve the reprogramming efficiency and fidelity. 
2.4.2 Complete chromatin reconfiguration at a given locus varies according to the local 
chromatin environment.   
Compared to other reprogramming processes such as germ cell reprogramming, nuclear 
transfer, and cell fusion, iPSC generation has a much lower efficiency and a higher error rate 
[185]. While the mechanism by which reprogramming is achieved during iPSC induction is not 
yet fully elucidated, in addition to the sequence-specific transcription factors used to make the 
iPSCs, nucleosome organization and histone modification status have been implicated.  During 
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the first 48 hours of induction of the Yamanaka reprogramming factors OCT3/4, SOX2, KLF4 
and c-MYC (OSKM), O, S, and K act as pioneer transcription factors and bind to DNase1 
resistant distal elements that lack covalent histone modifications [179].  These distal elements 
subsequently gain the H3K4me2 mark during reprogramming as the somatic enhancer signature 
is transformed into the ESC signature [186]. These events precede promoter activation and large-
scale transcriptional changes that ultimately delineate somatic cells from iPSCs.  
It is therefore important to identify and characterize determinants of differential DHS 
accessibility between iPSC and ESC to truly understand the nature of reprogramming, the 
characteristics of iPSCs, and to ultimately improve the efficiency and fidelity of in vitro 
reprogramming. We showed that the complete reconfiguration of chromatin structure might 
depend on the local chromatin environment of the starting cell population. This supports reports 
showing that chromatin modifying enzymes or drugs improve the efficiency of iPSC induction. 
For instance, addition of the chromatin-associated transcriptional repressor UTF1 to 
conventional Yamanaka factors (OCT3/4, SOX2, KLF4 and C-MYC) significantly improved the 
formation of iPSC clones [187]. In addition, either treatment with inhibitors of DNA 
methyltransferase (DNMT), or knocking down the MBD3 subunit of the NuRD repressor 
complex increased reprogramming efficiency [172,174].  It is possible that optimizing 
combinations of these and other chromatin remodelers will further improve the efficiency and 
fidelity of iPSC generation.   
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2.4.3 Chromatin that does not properly open or that remains improperly closed in iPSCs 
harbors features inherently resistant to reprogramming 
Both hESC dDHS sites and memory dDHS sites are regions at which the chromatin 
accessibility in hiPSC lines mimicked their progenitor lines and differed compared to hESC 
lines. It is possible that those genomic domains are generally more resistant to chromatin 
reconfiguration during reprogramming. It is not clear whether these refractory sites contribute to 
the low efficiency of iPSC generation in particular, or whether these loci are also problematic in 
other somatic reprogramming approaches.  
 Regions that are refractory to pioneer reprogramming factor binding have also been 
identified [179]. These megabase-sized regions are enriched for H3K9me3 and termed OSKM-
Differentially Bound Regions (OSKM-DBRs). In the small proportion of somatic cells that 
reprogram following OSKM induction these OSKM-DBRs become accessible.  Our study 
showed that genomic regions not reprogrammed to match the DHS profiles in hESC were 
enriched for repressive H3K9me3 and EZH2 in somatic skin fibroblasts.  Therefore, a subset of 
dCOREs identified by DNaseI hypersensitivity may reflect OSKM-DBRs.   
 The presence of specific sequence motifs at dDHS might provide a mechanistic link 
between site-specific reprogramming efficiency and transcription factors that act as drivers of 
differentiation and de-differentiation. Indeed, we have found over-representation of the KLF4 
motif at both hESC and hiPSC dDHS sites possibly indicating a direct role of Yamanaka factors 
themselves in failed reprogramming. In contrast, memory dDHS sites were enriched for AP-1 
motifs suggesting that persistent binding of AP-1 factors might hinder the chromatin remodeling 
at these locations. 
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Genetic differences between the hESC and hiPSC lines we analyzed might also 
contribute to the differences in chromatin accessibility between these samples. Recent analysis of 
DHS in 70 lymphoblastoid cell lines has revealed DNase  I sensitivity quantitative trait loci 
(dsQTLs) [188].  The stringent criteria we used to identify dDHS makes it likely that very few of 
the dDHS regions identified in this study are due to dsQTLs.  Future studies using iPS cells from 
larger numbers of individuals will be important to distinguish the precise contribution of dsQTLs 
and their impact on reprogramming potential. 
2.4.4 Imcompletely reprogrammed sites may become functionally relevant only upon 
differentiation of iPS cells.  
Pluripotent stem cells are revealing new insights into the chromatin regulatory 
mechanisms that control development.  DHS sites that define the landscape of differentiated cells 
are remarkably well represented even before the initiation of differentiation.  A recent study that 
produced DHS maps from ESCs and 48 definitive somatic cell types concluded that definitive 
cell types share on average 37% of the DHS sites found in undifferentiated ESCs [183].  
Therefore, during development, the majority of ESC DHS sites are lost, and smaller numbers of 
lineage-restricted DHS sites are activated de novo.  
In this study we examined a limited number of hESCs and hiPSCs cell lines and found 
that ~4% of the DHS sites showed differential accessibility between the two cell types. Despite 
these chromatin differences, transcript levels between hESCs and hiPSCs were almost 
indistinguishable. It seems that that dDHS sites are not essential for self-renewal, but are instead 
crucial for accurate gene regulation upon cellular differentiation. Indeed, most of the dDHS-
enriched genes or dCORE-connected genes such as ZIC2 and ZIC5, are not involved in 
pluripotency maintenance but are transcribed and involved in various cellular differentiation 
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processes. These findings echo results that found similar functions for aberrantly methylated 
genes [101]. In addition, memory dDHS sites are enriched for fibroblast super-enhancers that 
may harbor key regulatory elements only for lineage specific gene expression. The incomplete 
reprogramming at those lineage-specific regulatory elements are likely most problematic for 
differentiation, not the stem cell state.  
2.5 METHODS 
Cell culture.  Human ESC lines H1 (WA01-Feeder Independent), H7 (WA07-Feeder 
Independent), and H9 (WA09-Feeder Dependent) were obtained from WiCell.  Two skin 
fibroblast cell lines PF43 (AG20443) and PF95 (AG08395) were obtained from Coriell and 
cultured under recommended conditions using DMEM supplemented with 10% Fetal Bovine 
Serum, 2mM L-glutamine, and 0.1mM (0.7µl/100ml final media volume) 2-mercaptoethanol, 50 
units/ml penicillin, and 50 g/ml streptomycin. The reprogramming and derivation of human iPS 
cell lines NIHi7 (from PF95) and NIHi11 (from PF43) has been described [189].  H1 and H7 
cells were cultured on Matrigel in mTeSRTM1 medium.  Three replicates of NIHi7, three 
replicates of NIHi11, and two replicates of H9 hES cells were cultured on a feeder layer of 
irradiated CF1 mouse embryonic fibroblasts in hES media (DMEM-F12 (Invitrogen), 20% KSR 
(Invitrogen), 20ng/ml FGF2 (R&D Systems), 2mM L-glutamine, 0.1mM 2-mercaptoethanol, and 
1x non-essential amino acids.)  A third replicate of H9 hES cells was grown on Fibronectin in 
hES media.    
DNase-seq.  DNase-seq was performed as previously described [7]. Data was generated 
for two biological replicates of H1 cells, and three biological replicates of H7, H9, NIHi7, 
NIHi11, PF43, and PF95 cells. Human Affymetrix exon arrays were processed by Sheffield et al., 
and used to connect DHS sites with target genes [180].  
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DNase-seq data preprocessing and normalization. Sequencing data were processed 
and mapped to NCBI build 37/hg19 human reference genome, and DHS sites were mapped using 
standard pipeline, as described previously [7]. Data are publicly available on the UCSC Genome 
Browser (http://genome.ucsc.edu) and at the Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo) under accession number GSE32970. DHS sites mapped in 
each replicates were ranked by their p-values. Top 100K DHS sites from each sample were used 
for analysis. For each cell type, the number of mapped sequence tags was counted at each base 
(base count) in each DHS site. Counts were normalized and scaled using the following formula: 
Normalized base count = base count x 109 / (total number of mapped tags in all DHS x total 
length of all DHS) 
Microarray protocol and normalization.  Affymetrix Human Exon 1.0 ST microarray 
data were generated as described by Song et al. [7] from four replicates of H1 cells, three 
replicates of H7, H9, PF43, and PF95 cells, and two replicates of NIHi7, NIHi11.  Exon arrays 
were processed and normalized by Sheffield et al. [180].  Data are publicly available on the 
UCSC Genome Browser (http://genome.ucsc.edu) and GEO under accession number GSE15805. 
For each gene, the average expression level in all hESC samples and hiPSC samples were 
calculated separately. Average expression levels in hESCs and hiPSCs were plotted using 
function smoothScatter in R Bioconductor Package geneplotter (v1.38.0) in Fig. 6A.  
Overall comparison of DHS sites from hESCs, hiPSCs, and fibroblasts.  Intersect sets 
of top 100K DHS sites from replicates of hESCs (53,250 intersect sites), hiPSCs (79,190 
intersect sites), and fibroblasts (84,263 intersect sites) were generated using BEDTools suite 
(version 2.16.1) [53]. The intersect sets of DHS sites from three cell types were compared to 
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each other using BEDTools suite. The results were plotted using Venn Diagram Plotter 
(http://omics.pnl.gov/software/VennDiagramPlotter.php) as shown in Figure S2. 
Clustering analysis.  A union set of 212,986 DHS sites of top 100K DHS sites from all 
hESC, hIPSC, and fibroblasts was created using BEDTools suite. The number of mapped 
sequence tags in each union site was counted, and then normalized by the length of the site and 
the number of all mapped tags in each sample. Normalized tag counts were used to cluster 
samples in the chromatin space. RNA expression levels measured on Affymetrix exon arrays 
were used to cluster samples in the transcription space. Principle component analysis (PCA) and 
hierarchical clustering were performed using function prcomp and hclust available in the R 
statistical package (http://www.r-project.org). Hierarchical clustering results were visualized 
using function ColorDendrogram available in R package “sparcl” [190]. 
Identification of differential DHS sites.  Union sets of top 100K DHS sites of hESCs 
(142,412 union sites), hiPSCs (118,089 union sites), and fibroblasts (113,917 union sites) were 
generated using BEDTools suite. Intersect (defined above) and union DHS sites of hESCs, 
hiPSCs, and fibroblasts were compared to each other using BEDTools. Specifically, 2,010 dDHS 
sites were mapped only in hESCs by subtracting hiPSC union sites and fibroblast union sites 
from hESC intersect sites. Similarly, 1,393 dDHS sites were mapped only in hiPSCs by 
subtracting hESC union sites and fibroblast union sites from hiPSC intersect sites. 978 memory 
sites were identified by subtracting hESC union sites from the intersect of hiPSC intersect sites 
and fibroblast intersect sites. The results were plotted using Venn Diagram Plotter in Fig. S2. 
R package edgeR (version 3.0.8) [175] was used to identify DHS sites that had 
significantly different amplitudes of DNase signal between hESCs and hiPSCs. After creating a 
union set of 158,393 DHS sites for hESCs and hiPSCs, each union DHS site was divided into 
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non-overlapping 500bp windows starting from the center of the site. From this analysis, 375,371 
500bp windows were obtained.  The number of mapped DNase-sequence tags in each 500bp was 
counted and used as input for edgeR analysis. Windows that had significantly different 
amplitudes between hESCs and hiPSCs were identified using a cutoff of FDR adjusted p-value 
0.05. Adjacent windows that had a significant threshold were merged. Overall, in addition to the 
2,010 dDHS sites that were mapped only in hESCs (as described above), 590 loci had 
consistently higher amplitudes in hESCs relative to hiPSCs. Together 2,600 DHS sites were 
defined as hESC dDHS sites. Similarly, in addition to the 1,393 dDHS sites mapped only in 
hiPSCs (as described above), 828 loci had consistently higher amplitudes in hiPSCs than in 
hESCs. Together 2,221 DHS sites were defined as hiPSC dDHS sites.  Idiogram of dDHS sites 
(Fig. 3A and Fig. S3A) was generated using Idiographica (http://www.ncrna.org/idiographica) 
[191].  
Identification of dCOREs.  dCOREs were defined as a stretch of dDHS sites among 
which each dDHS site was within 10kb of another dDHS site of the same type, using function 
cluster in BEDTools suite. The coordinates of each type of dDHS sites were permutated over the 
genomic space of the 212,986 union DHS sites from hESCs, hiPSCs, and fibroblasts (defined 
above). Clusters of permutated dDHS sites were identified in the same way as dCOREs. 
Idiogram of dCOREs was generated using Idiographica (Fig. S3B). 
Comparison of dDHS sites and dCOREs to DMRs, OSKM-DBRs, and super-
enhancers. Genome coordinates of CG- and non-CG mega-DMRs identified by Lister et al. [99], 
and coordinates of OSKM-DBRs [179] were converted from NCBI build 36/hg18 to NCBI build 
37/hg19 human reference genome using UCSC genome browser tool Batch Coordinate 
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Conversion (liftOver) (http://genome.ucsc.edu/cgi-bin/hgLiftOver). dDHS sites and dCOREs 
were compared to DMRs, OSKM-DBRs, and super-enhancers using BEDTools suite. 
Histone modifications in dDHS sites in fibroblasts. Three types of control DHS sites 
were used to compare to dDHS sites.  1) permuting coordinates of hESC dDHS sites in the 
genomic space of DHS sites that were shared by hESCs and hiPSCs but not fibroblasts (i.e. DHS 
sites that were successfully opened during reprogramming), 2) permuting coordinates of hiPSC 
dDHS sites in genomic regions that did not present a DHS site in hiPSC, hESC, or fibroblasts but 
were previously identified as a DHS site in at least one of the other samples of the 112 samples 
examined in the previous study [180] (i.e. regions that faithfully remained closed during 
reprogramming), and 3) permuting coordinates of memory dDHS sites in genomic space of 
fibroblast DHS sites that were closed in hiPSCs and hESCs (i.e. regions that was successfully 
closed during reprogramming). 1000 sets of control sites were generated from 1000 permutations 
for each type of dDHS sites.  
 ENCODE ChIP-seq data of histone modifications H3K9ac, H3K27ac, H3K4me1, 
H3K4me2, H3K4me3, H3K36me3, H3K79me2, H4K20me1, H3K9me3, and H3K27me3, 
histone variant H2A.Z, and insulator protein CTCF on the skin fibroblast cell line NHDF-Ad and 
the primary fibroblast cell line AG04450 were downloaded from the UCSC Genome Browser. 
From each dataset, the number of mapped sequence tags in each dDHS site and each control site 
was counted and normalized by the length of the site and the total number of mapped sequence 
tags in that dataset. The average of normalized tag densities in each type of dDHS sites and each 
set of its corresponding control sites was calculated. The average normalized density of dDHS 
sites was plotted in red dots in Fig. S4, while the distribution of the average normalized tag 
densities in 1000 control sets was represented in boxplots. The difference between the average 
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normalized tag density in dDHS sites and the mean of the average tag densities in its 1000 set of 
control sites was calculated, and presented in unit of the standard deviation (SD) of the 1000 
average normalized densities from 1000 control sets (Fig 4 and Fig. S4). It can be formulized as: 
(Average normalized density dDHS – mean (Average normalized density 1000 control sets) ) /  
SD (Average normalized density 1000 control sets). 
An empirical p-value was calculated for each comparison: 
p-value = # of control sets that had smaller (or bigger) average normalized density than that of 
the dDHS sites / 1000 
Motif analysis and overlap with ChIP-seq data.  DNA sequences of dDHS sites were 
extracted from the UCSC Genome Browser. De novo motif search in dDHS sites was performed 
using MEME-ChIP (http://meme.nbcr.net/meme/cgi-bin/meme-chip.cgi) [192]. Motifs identified 
with e-values < e-10 were reported. The frequency of AP-1 motif in memory dDHS sites was 
scanned using FIMO (http://meme.nbcr.net/meme/cgi-bin/fimo.cgi) [193].  ENCODE ChIP-seq 
peaks of FOSL2 and JUND in A549 (Human lung adenocarcinoma epithelial cell line) were 
downloaded from the UCSC Genome Browser. The overlap between A549 FOSL2 and JUND 
ChIP-seq peaks and dDHS sites was determined using BEDTools suite. 
Genome annotation.  Location of dDHS sites relative to genes was annotated using 
function annotatePeaks in HOMER (version v3.17) (Hypergeometric Optimization of Motif 
EnRichment) suite [54] with default UCSC RefGene annotation. Promoters were defined as 
transcriptional start sites (TSSs) ±1000  bp. Transcription termination site (TTS) regions were 
defined as from -100 bp to +1kb of TTS.  
Connecting dDHS sites and dCOREs to genes.  To connect all DHS sites including 
dDHS sites to their target genes, we used a previously developed methodology [180]. The 
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underlying premise of the method is that if the amplitude of a DHS site was significantly 
positively or negatively correlated with the expression level of a gene across many cell lines, that 
DHS site was then considered to be connected to that gene. For each DHS site, all genes with at 
with a TSS within 100 kb were examined. To determine correlations between DNase-seq and 
expression array data, 112 different cell lines and tissues across 72 diverse cell types from 
ENCODE and Roadmap Epigenomics project were used, including the hESC and hiPSC lines 
used in this study. The union set of ~2.7M DHS sites from all 112 datasets were connected to 
31,429 genes, representing 781,679 connection events at a cutoff of p-value 0.05. In some cases, 
individual DHS sites were connected to multiple genes, and in some cases multiple DHS sites 
were connected to the same gene. 
45,153 of the 158,393 hESCs and hiPSCs union DHS sites were connected to 24,529 
genes using this connection matrix, including 2,483 of the 5,799 dDHS sites. For each of those 
connected genes, the number of connected union DHS sites and the number of connected dDHS 
sites were counted. To identify genes that were enriched for dDHS site connections, the 
following exact binomial test was performed on each gene using R function binom.test: 
binom.test(x=# of connected dDHS sites, n=# connected union DHS sites, p=2483/45143, 
alternative = "greater”).   
All connected genes were then ranked by their FDR-adjusted p-values from the binomial 
test. The smaller the p-value is, the more enriched the gene is for dDHS site connections.  To 
confirm the results of the exact binomial test, we also performed permutation-based analysis. 
Coordinates of dDHS sites were permutated in the genomic space of the 158,393 hESCs and 
hiPSCs union DHS sites. Permutated dDHS sites were connected to genes using the same 
connecting matrix. For each gene, the number of connected permutated dDHS sites was counted. 
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1000 permutations were performed. For each gene, the number of connected true dDHS sites was 
compared to numbers of connected permutated dDHS sites from the 1000 permutation. An 
empirical p-value was calculated as:  
p-value = # of permutations in which the # of connected permutated dDHS sites was bigger than 
the # of connected real dDHS sites / 1000 
The results of simulation studies of the top 20 genes from the binomial test were plotted 
in Fig. S5C. The permutation based p-values agreed well with the binomial test results (Table 
S3).  We repeated the connection analysis and the bionomial test on each type of dDHS sites 
separately. hESC dDHS enriched genes,  hiPSC dDHS enriched genes, and memory dDHS 
enriched genes were similarly defined at a cutoff of FDR-adjusted p-value 0.05. Similarly, we 
connected each type of dCOREs to genes. Genes connected to at least one dCORE were 
reported.  
Gene ontology analysis.  Gene ontology (GO) terms of the top 100 genes that were 
enriched for dDHS site connections were extracted using GATHER 
(http://gather.genome.duke.edu/) [194]. The 100 genes were manually grouped into six general 
categories based on the keywords in their GO term annotations (Fig. 5A). GO term enrichment 
analysis (Table S6) of hESC dDHS enriched genes, hiPSC dDHS enriched genes, and memory 
dDHS enriched genes were performed using DAVID (Database for Annotation, Visualization 
and Integrated Discovery) Bioinformatics Resources 6.7, (http://david.abcc.ncifcrf.gov/) 
[195,196].  
Identification of genes that were differentially expressed after mesendodermal or 
neurectodermal differentiation.  Expression data of undifferentiated and differentiated hESCs 
H1, H7, H9 and hiPSCs NIHi7 and NIHi11 measured on Agilent human One Color Gene 
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Expression Oligo microarrays were downloaded from http://stemcelldb.nih.gov [182]. Raw data 
were quantile normalized than log2 transformed. To identify genes that were significantly up- or 
down-regulated during mesendodermal or neurectodermal differentiation, we used microarray 
analysis tool Significance Analysis of Microarrays (SAM) version 4.0 [197] and a cutoff of q-
value < 0.05 and fold change >2. 
2.6 Data Access  
All DNase-seq and expression datasets have been deposited in Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE32970 and GSE15805. 
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2.7 Supplemental data  
 
Figure 2.8.  hiPSC and hESC lines have similar expression profiles.  Replicates of hiPSC 
lines clustered with replicates of hESC lines and were separated from their parental fibroblast 
lines in expression space by both PCA clustering (A) and hierarchical clustering (B). 
 
 
 
 
 
 
Figure 2.9.  Identification of hESC-, hiPSC-, and fibroblast-specific DHS sites.  A) hESC-
specific DHS sites (n=2,010) were identified by taking the intersection of all DHS sites identified 
from the H1, H7, and H9 cell lines, and subtracting the union set of DHS sites from both hiPSC 
and fibroblast lines.  B) hiPSC-specific DHS sites (n=1,392) were identified similary using 
method described in (A). C) fibroblast-specific DHS (i.e. memory dDHS) sites (n=978) were 
identified by taking the intersection of all DHS sites from hiPSCs and fibroblast lines and 
subtracting the union set of DHS sites from hESC lines. 
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Figure S1 (Related to Figure 1).  hiPSC and hESC lines have similar expression 
profiles.  Replicates of hiPSC lines clustered with replicates of hESC lines and were 
s parated from their parental fibroblast lines in expression space by both PCA clustering 
(A) and hierarchical clustering (B). 
Fig. S1 Zhang et al.  
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Figure S2 (Related to Figure 2).  Identification of hESC-, hiPSC-, and fibroblast-specific 
DHS sites. A) hESC-specific DHS sites (n=2,010) are identified by taking the intersection of 
all DHS sites identified from the H1, H7, and H9 cell lines, and subtracting the union set of 
DHS sites from both hiPSC and fibroblast lines.  B)  hiPSC-specific DHS sites (n=1,393) are 
identified similarly using method described in (A). C) fibroblast-specific DHS (i.e. memory 
dDHS) sites (n=978) are identified by taking the intersection of all DHS sites from hiPSC and 
fibroblast lines, and subtracting the union set of DHS sites from hESC lines.  
Fig. S2 Zhang et al.  
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Figure S2 (Related to Figure 2).  Identification of hESC-, hiPSC-, and fibroblast-specific 
DHS sites. A) hESC-specific DHS sites (n=2,010) are identified by taking the intersection of 
all DHS sites identified from the H1, H7, and H9 cell lines, and subtracting the union set of 
DHS sites from both hiPSC and fibroblast lines.  B)  hiPSC-specific DHS sites (n=1,393) are 
identified similarly using method described in (A). C) fibroblast-specific DHS (i.e. memory 
dDHS) sites (n=978) are identified by taking the intersection of all DHS sites from hiPSC and 
fibroblast lines, and subtracting the union set of DHS sites from hESC lines.  
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DHS sites. A) hESC-specific DHS sites (n=2,010) are identified by taking the intersection of 
all DHS sites identified from the H1, H7, and H9 cell lines, and subtracting the union set of 
DHS sites from both hiPSC and fibroblast lines.  B)  hiPSC-specific DHS sites (n=1,393) are 
identified similarly using metho  described in (A). C) fibroblast-specific DHS (i.e. memory 
dDHS) sites (n=978) are identified by taking the intersection of all DHS sites from hiPSC and 
fibroblast lines, and subtracting the union set of DHS sites from hESC lines.  
Fig. S2 Zhang et al.  
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Figure 2.10. Differential DHS (dDHS) sites and dCOREs cluster nonrandomly across the 
genome and are connected to developmental genes. A) Each hESC dDHS, hiPSC dDHS, and 
memory dDHS site was mapped to the genome. hESC and hiPSC dDHS sites often clustered 
together in close proximity.  The X chromosome contained mostly hiPSC dDHS sites. B) 
Location of dCORES relative to each chromosome.  C) Number of dDHS sites within dCORES 
and genes that are connected to these dDHS sites.  D-F) List of genes that are connected to hESC 
dCOREs (D), hiPSC dCOREs (E), and memory dCORE (F). 
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Figure S3 (Related to Figure 3). Differential DHS (dDHS) sites and dCOREs cluster non-
randomly across the genome and are connected to developmental genes.  A) Each hESC 
dDHS, hiPSC dDHS, and memory dDHS site was mapped to the genome. hESC and hiPSC 
dDHS sites often clustered together in close proximity.  The X chromosome contained mostly 
hiPSC dDHS sites. B) Location of dCORES relative to each chromosome.  C) Number of dDHS 
sites within dCORES and genes that are connected to these dCOREs. D-F) List of genes that 
are connected to hESC dCOREs (D), hiPSC dCOREs ( ), and memory dCOREs (F). 
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Figure 2.11. The local chromatin environment in differentiated somatic cells prior to 
reprogramming – AG04450.  Similar to Figure 4 in the main text, but ChIP-seq data from 
AG04450 fibroblast cell line was compared to regions identified as hESC dDHS (A), hiPSC 
dDHS (B) and memory dDHS (C).  For each panel, active histone marks are on the left, while 
repressive marks are on the right. A) hESC dDHS (blue line) were compared to control DHS 
sites (black line) that were present in hiPSCs and hESCs, but not fibroblasts (see inset for 
pictorial representation).  Direction of significant enrichment is shown by red (higher) and green 
(lower) arrows.  Black arrows are not significantly different. Relative to control sites, hESC 
dDHS sites had lower levels of active histone marks and higher level of repressive histone 
marks. B) hiPSC dDHS (blue line) were compared to control DHS sites (black line) that were not 
present in any of the three cell types.  Relative to control sites, hiPSC dDHS sites had higher 
levels of both active histone marks and repressive histone marks. C) Memory dDHS sites (blue 
line) were compared to control DHS sites (black line) that were only present in fibroblasts.  
Relative to control, memory dDHS sites had higher levels of active histone marks.  The right part 
of figure represents distribution of random permutations. 
 
0
10
20
30
40
no
rm
al
ize
d 
de
sn
ity
CTCF
11
.1
 S
D
3.
8 
SD
3.
3 
SD
0.
7 
SD
0.
5 
SD
H3K27ac H3K4me3 H3K9me3 H3K27me3
iPSCs
ESCs
fibroblasts
memory
dDHS
control
0
20
40
60
80
2.
8 
SD
1.
9 
SD
2 
SD
2.
7 
SD
4 
SD
CTCF H3K27ac H3K4me3 H3K9me3 H3K27me3
iPSCs
ESCs
fibroblasts
ESC
dDHS
control
no
rm
al
ize
d 
de
sn
ity
CTCF H3K27ac H3K4me3 H3K9me3 H3K27me3
iPSCs
ESCs
fibroblasts
iPSC dDHS control
no
rm
al
ize
d 
de
sn
ity
active mark repressive mark
A
B
C
*
*
*** **
** **
**
Empirical p-vlaue:
    p-value < 0.05
   p-value < 0.005
    
***
0
5
0
1
0
0
1
5
0
CTCF H3K27ac H3K4me3 H3K9me3 H3K27me3
CTCF H3K27ac H3K4me3 H3K9me3 H3K27me3
0
1
0
2
0
3
0
4
0
5
0
CTCF H3K27ac H3K4me3 H3K9me3 H3K27me3
active mark repressive mark
Lower signal
Higher signal
No significant difference
Control
dDHS
5
1
0
1
5
0
2
4
6
8
10
10
.6 
SD
2 S
D
3.2
 SD
1 S
D 5
.6 
SD
** ****
*
Fig. S4 Zhang et al.  
Figure S4 (Related to Figure 4). The local chromatin environment in differentiated 
somatic cells prior to reprogramming – AG04450.  Similar to Figure 4 in the main text, 
ChIP-seq data from AG04450 fibroblast cell line was analyzed at regions identified as hESC 
dDHS (A), hiPSC dDHS (B) and memory dDHS sites (C).  For each panel, active histone 
marks are on the left, while repressive marks are on the right. A) hESC dDHS (blue line) were 
compared to control DHS sites (black line) that were present in hiPSCs and hESCs, but not 
fibroblasts (see inset for pictori l representation).  Direction of significant enrichment is shown 
by red (higher) and green (lower) arrows.  Black arrows are not significantly different. Relative 
to control sites, hESC dDHS sites had lower levels of active histone marks and higher level of 
repressive histone marks. B) hiPSC dDHS (blue line) were compared to control DHS sites 
(black line) that were not present in any of the three cell types.  Relative to control sites, 
hiPSC dDHS sites had higher levels  both active histone marks and repressive histone 
marks. C) Memory dDHS sites (blue line) were compared to control DHS sites (black line) that 
were only present in fibroblasts.  Relative to control, memory dDHS sites had higher levels of 
active histone marks.  The right part of figure represents distribution of random permutations.  
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Figure 2.12.  Motif enrichment, genomic location, and gene connectivity of dDHS sites.  A) 
De novo motif detection was performed on hESC dDHS, hiPSC dDHS, and memory dDHS sites.  
B) Location of dDHS sites relative to genes.  Shown are the location of different classes of 
dDHS sites relative to promoter, intron, exon, transcription termination site (TTS), and intergenic 
regions.  “Genomic” represents the total genome coverage for each classification. C) The top 20 
genes that are most connected to dDHS sites, described in Figure 5, were analyzed by 
permutation testing (box plots).  Each of the 20 genes were shown to have significantly more 
connections to dDHS sites (red circles) than the permutation datasets. 
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Fig. S5 Zhang et al.  
Figure S5 (Related to Figure 5). Motif enrichment, genomic location, and gene connectivity of 
dDHS sites. A) De novo motif enrichment detection for hESC dDHS, hiPSC dDHS, and memory 
dDHS sites.  B) Location of dDHS sites relative to promoter, intron, exon, transcription termination site 
(TTS), and intergenic regions.  “Genomic” represents the total genome coverage for each 
classification. C) The top 20 genes that are most connected to dDHS sites (red circles), described in 
Fig. 5A, have significantly more connections to dDHS sites than the permutation datasets (boxplots). 
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Figure 2.13.  Location of dDHS sites surrounding key developmental genes.  Screenshots of 
hESC dDHS sites (gray boxes) at SOX2, FOXA1, HMX2/HMX3, and HOXA gene loci. ESC 
dDHS sites around SOX2 overlapped with a hESC super-enhancer (red bar) identified in H1 
ESCs. 
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Figure 2.14.  Differential DHS sites at gene loci foreshadow expression misregulation upon 
in vitro differentiation. A) ZIC2 and ZIC5, SOX21, OTX2, and BMP4, were enriched for hESC 
dDHS sites (gray boxes), and were insufficiently up-regulated in hiPSCs upon mesendodermal 
differentiation. hESC dDHS sites at ZIC2/ZIC5 and SOX21 loci overlapped with hESC super-
enhancers (red bar). B) PLB1 was enriched for hiPSC dDHS sites (gray box in the middle) and 
memory dDHS sites (the remaining gray boxes), and was improperly up-regulated in hiPSCs 
upon neuroectodermal differentiation. 
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CHAPTER III: 
INITIAL DEMONSTRATION OF A STRATEGY FOR EN MASSE FUNCTIONAL 
CHARACTERIZATION OF HUMAN ENHANCER ELEMENTS 
 
3.1 OVERVIEW 
We developed a method for highly parallel measurement of the functional activity of 
putative regulatory elements isolated from open chromatin in a given cell type. Our assay 
consists of cloning FAIRE-enriched DNA (Formaldehyde Assisted Identification of Regulatory 
Elements) into GFP-based enhancer reporter vectors, transfecting cells with the reporter 
constructs, sorting for GFP-positive cells, recovering the inserts from the reporter, and 
sequencing them. Each FAIRE-enriched fragment is tested in the forward and reverse orientation 
relative to the reporter gene. Here we report an initial demonstration of this assay in HEK293T 
cells. Among 26,046 FAIRE sites identified by stringent criteria in HEK293T cells, 3,428 (13%) 
were enriched in GFP-positive cells in both orientations. We found that relative to all FAIRE 
fragments, the 3,428 regions were on average further from transcription start sites, and that 
motifs of eleven known transcription factors, including known enhancer-binding factors AP-1 
and Foxa2, were enriched in those regions. In addition, genes that were near these 3,428 regions 
were expressed at higher levels than overall gene expression levels in HEK293T cells. Thus we 
identified 3,428 open chromatin regions associated with orientation-independent activation of a 
reporter in HEK293T cells, demonstrating the feasibility of functional characterization of several 
thousand enhancer elements in a single experiment of this design. 
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3.2 INTRODUCTION 
Gene regulatory elements are short non-coding genomic regions that regulate the 
transcription of genes. These elements can act as promoters, enhancers, insulators and silencers, 
and are typically bound by sequence-specific transcription factors. The binding of sequence-
specific regulatory factors is usually accompanied by nucleosome loss, a hallmark of regulatory 
activity in eukaryotic cells [5,14,15]. These nucleosome-depleted regions or “open chromatin” 
can be detected through methods like DNase I hypersensitivity [5,6,8,15,25] or FAIRE 
(Formaldehyde Assisted Identification of Regulatory Elements) [7,14,26,27]. The results of these 
methods can be quantitatively measured across the genome in a single experiment by 
quantitative PCR, microarray, or high-throughput sequencing.  
FAIRE has been used to annotate regulatory elements in dozens of human cell types and 
tissues [7,27,31]. There are typically about 100,000 FAIRE sites per cell type. Of these, only 
~10% of FAIRE sites overlap transcriptional start sites (TSSs) or are within 2 kb of a TSS [7,27]. 
Therefore, most putative regulatory sites identified by FAIRE are non-promoter distal elements. 
A large proportion of these distal elements are putative enhancers, many of which play key roles 
in the control of cell-type-specific gene expression programs [140,198-202]. A typical 
mammalian cell contains tens of thousands of active enhancers, and it has been estimated that 
there may be more than 1 million enhancers active across all human cell types [8,31,111]. These 
distal enhancers can be located upstream, downstream or within their target genes, and can 
modulate expression independent of their orientation [139,140,198,199,201]. Some have been 
found at large genomic distances from their targets [141,142], or even on a different 
chromosome[143,144]. Identifying and functionally annotating these distal elements is important 
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for understanding normal cell biology and for understanding the disease-associated sequence 
variation that occurs in these regulatory elements [146,147,203-206].  
While DNase I, FAIRE, ChIP and other methods have made identification of putative 
regulatory elements routine, those methods do not provide information regarding the functional 
activity of each element. Determining the function of putative regulatory elements is currently a 
major bottleneck in the study of gene regulation. Traditionally, regulatory elements have been 
functionally characterized one or a few at a time through serial transfection of individual 
reporters [112,117,118,121-124], but more recently DNA elements have been characterized 
using systematic large-scale approaches [95,97,98,138]. One such high-throughput functional 
method was designed to characterize promoter regions in the human genome [138]. In this study, 
random fragments from sheared genomic DNA were cloned into a GFP-based promoter reporter 
vector and tested for their ability to drive GFP reporter expression in cell culture. While they 
identified 858 putative promoters, this approach is highly inefficient as active regulatory 
elements in each cell type occupy less than 5% of the genome. Therefore most cloned fragments 
will not be functional. Other studies developed massively parallel reporter assays to test enhancer 
activities of either a few known human enhancers and a large number of their engineered 
variants [95,97] or a few thousand predicted enhancers and their variants [98]. Despite the 
success of those studies, it should be noted that the tested enhancers were synthesized from 
known or predicted enhancer sequences. Such synthesis-based approaches are costly and require 
exact DNA sequences of tested elements, thus it is hard to adapt these to the genome-wide 
annotation of thousand of native enhancers in a given human cell type of which many are 
unknown elements. 
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In this study, we developed a highly parallel genome-wide method for measuring the 
enhancer activity of native putative regulatory elements identified by FAIRE in a given human 
cell type. To demonstrate the utility of this assay, we tested FAIRE-enriched DNA from 
HEK293T cells. Of 26,046 regions of open chromatin identified by stringent criteria in these 
cells, we identified 3,428 sites associated with orientation-independent enhancer activity. These 
regions were found to be more distal than typical FAIRE elements, and showed enrichment for 
eleven transcription factor binding motifs including for AP-1 and Foxa2. In addition, genes that 
were near these 3,428 regions were expressed at higher levels than overall gene expression levels 
in HEK293T cells. Thus, functionally identifying several thousand enhancer elements in a single 
experiment is feasible with a design based on ours, which represents a 100-fold increase in 
throughput relative to traditional serial approaches. 
3.3 RESULTS 
3.3.1 A high-throughput method to test enhancer function of FAIRE-enriched DNA 
fragments. 
Each FAIRE experiment identifies approximately 100,000 active regulatory elements in 
any given cell type. Testing the function of each of the putative regulatory elements is a daunting 
challenge. We aimed to interrogate the enhancer activity of most or all of these elements in a 
single high-throughput reporter assay. In our assay, each putative regulatory element is tested for 
its ability to induce the expression of a GFP reporter gene (Figure 3.1A).  FAIRE fragments 
were cloned en masse into a Gateway entry vector and then transferred to a GFP-based enhancer 
reporter vectors through the Gateway cloning system (Figure 3.1B). Two enhancer reporter 
vectors were constructed, which contained Gateway attR1-R2 sites (forward reporter vector) or 
attR2-R1 sites (reverse reporter vector) upstream of a E1B minimal promoter [207,208] and the 
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GFP gene. In this way, FAIRE fragments were inserted 69 bp upstream of the GFP gene in both 
orientations. This design allowed us to test whether the function of each insert was orientation-
independent, traditionally a defining feature of enhancers [139,140,198,199,201]. Cells were 
transfected with either forward or reverse reporter constructs and sorted based on GFP intensity. 
Cells transfected with the positive control construct that contains the SV40 enhancer and cells 
transfected with the negative control construct that contains no insert were used to set the gating 
parameters in the fluorescence-activated cell sorting (FACS). Inserts in the entry vector, reporter 
vectors, and GFP-positive cells were recovered by PCR amplification. The raw FAIRE 
fragments and recovered FAIRE inserts were also sequenced and analyzed.  
It should be noted that not all cloned DNA fragments in our library originate from open 
chromatin regions. About 100,000 open chromatin regions are identified in a typical FAIRE 
experiment, covering ~1% of the genome. FAIRE DNA libraries are estimated to be 20 to 50-
fold enriched for active regulatory regions based on qPCR measurements [14,26]. If one assumes 
that 1% of the genome is within open chromatin, a library with 20-fold enrichment of open 
chromatin over background by FAIRE will consist of 17% FAIRE DNA fragments. Similarly, if 
the proportion of the genome in open chromatin is 5% and the enrichment is 20-fold, the 
proportion of FAIRE fragments in the library is 50%. In any case, our starting FAIRE library is a 
mixture of DNA from putative active regulatory regions (FAIRE sites) and background genomic 
regions.  
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Figure 3.1. Experiment design for high-throughput characterization of enhancer activities 
of open chromatin regions isolated by FAIRE.  A) Schematic representation of the enhancer 
reporter assay. FAIRE fragments were cloned upstream of E1B minimal promoter and GFP gene 
in the reporter vector. Reporter vector with no insert and vector with an SV40 enhancer were 
used as negative and positive controls, respectively. The enhancer activity of tested FAIRE 
fragments was shown by their ability to drive GFP expression.  B) Experiment design. FAIRE 
fragments were isolated from HEK293T cells, cloned into Gateway entry vector, transferred into 
two reporter vectors in which the FAIRE insert was upstream of the GFP gene in both 
orientations through Gateway recombination system. These FAIRE constructs were transfected 
into HEK293T cells. GFP-positive cells were collected in FACS. FAIRE fragments were 
recovered and sequenced from six libraries: the original FAIRE DNA, Gateway entry vector, 
forward reporter vectors, reverse reporter vectors, GFP-positive cells transfected with forward 
reporter vectors, and GFP-positive cells transfected with reverse reporter vectors (See Methods). 
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Another consideration is that the original FAIRE reaction used to make the library was 
performed on approximately ~250 million cells, meaning that theoretically ~500 million copies 
of each genomic locus were available for inclusion in the starting library. Approximately 15% of 
the FAIRE DNA (2 µg) was used in the Gateway cloning. Because DNA from both open 
chromatin and genomic background are equally likely to be cloned into Gateway vectors, the 
proportion of active regulatory elements in the Gateway entry vector library should reflect the 
proportion in the starting FAIRE reaction. In our case, one bottleneck for preserving the 
complexity of the library was the number of bacterial colonies that were collected following 
creation of the library in the Gateway entry vector.  Each colony contains one vector that carries 
one DNA segment. To ensure that most of the approximately ~26,000 stringent open chromatin 
sites were cloned into a Gateway entry vector, 300,000 colonies were collected and assayed for 
enhancer activity. 
Three independent transfection and FACS experiments were performed in each 
orientation, for a total of six experiments. In each FACS experiment, cells transfected with the 
positive or negative control vector were used to set the FACS gating parameter. The gate was set 
such that no negative control cells were in the “GFP bright” region (Figure 2B). Using this 
setting, approximately 5% of the positive control cells were in the GFP-bright region, which we 
considered GFP-positive. Cells transfected with libraries of FAIRE-enriched reporter constructs 
were sorted using the same gating parameters. Only GFP-positive cells were collected. In each of 
the six experiments, approximately 5,000-8,000 GFP-positive cells were collected from a total of 
~10M transfected cells (Figure 2). PCR amplification from the cell lysate was used to recover 
~650-bp DNA fragments. Due to the design of the primers, these PCR amplicons contained both 
vector and insert DNA. These fragments were then sheared to ~100-200 bp for sequencing 
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library preparation. Sequencing reads from all three experiments of each orientation were aligned 
to reference genome separately then pooled for downstream analyses.  
 
 
Figure 3.2. Collecting GFP-positive cells in fluorescence activated cell sorting (FACS). 
Gates were set in PE vs. FITC scatter plots (A) and FITC vs. FSC plots (B). A threshold was 
chosen such that no negative control cells were in the P3 GFP bright region (B). Only cells in P3 
GFP-bright region were considered GFP-positive and were collected. Using this gating, ~5% of 
the positive control cells were GFP-positive. 
 
3.3.2 3,428 DNA elements associated with orientation-independent enhancer activity were 
identified 
We identified FAIRE regions with enhancer activity by comparing the sequences 
recovered from the original FAIRE enrichment, the entry vector library, the reporter vector 
libraries, and GFP-positive cells. FAIRE regions enriched in the original FAIRE experiment 
were identified using ZINBA [52]. To reduce false positive rates and generate a high-confidence 
set of FAIRE regions, a stringent ZINBA threshold was used to identify 26,046 FAIRE sites 
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(Table S1). Sequences from the entry vector library, reporter vector libraries, and GFP-positive 
cells were aligned to reference human genome NCBI GRCh37 (hg19), and genomic regions 
whose DNA was enriched in each library were again identified by ZINBA (Table 1). It should 
be noted that we used a standard transient-transfection protocol that can result in multiple 
reporter vectors in each transfected cell [209,210]. Therefore, multiple inserts may be present in 
GFP-positive cells, only one of which may have enhancer activity. Nonetheless, we reasoned that 
true enhancer elements would consistently induce expression of the reporter gene across all 
independent replicates, and that by combining data from the independent transfection 
experiments, we would increase the ratio of true positives to false positives. In addition, we used 
the following computational criteria in downstream analyses to reduce the false positive rate. 
Regions identified as associated with enhancer activity must 1) be enriched in the starting FAIRE 
library; 2) be enriched in both forward and reverse GFP-positive libraries; and 3) be present in 
the entry vector, forward, and reverse reporter libraries. Selecting elements with activity in both 
orientations not only confirms a traditional defining property of enhancers, but also represents 
independent observations of activity of the same DNA segment. 
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Sample # of total reads # of aligned reads 
(Aligned %) 
# of FAIRE/ 
enriched regions 
FAIRE 57,046,446 43,787,792 
(76,76%) 
26,046 
Entry Vector 145,273,195 4,289,053 
(2.95%) 
21,132 
Forward Reporter Vector 195,447,256 6,885,125 
(3.52%) 
23,782 
Reverse Reporter Vector 190,425,149 6,917,432 
(3.63%) 
23,941 
Forward GFP-positive cells 60,960,333 10,103,201 
(16.57%) 
23,619 
Reverse GFP-positive cells 45,021,375 8,907,007 
(19.78%) 
24,003 
 
Table 3.1. Sequencing depth, number of mapped reads, and enriched FAIRE sites in six 
libraries. FIARE fragments from six libraries were sequenced and analyzed: the original FAIRE 
DNA, Gateway entry vector, forward reporter vector, reverse reporter vectors, GFP-positive cells 
transfected with forward reporter vectors, and GFP-positive cells transfected with reverse 
reporter vectors.  
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Figure 3.3. Most enhancer positive regions appeared to be distal regulatory elements that 
drove the expression of nearby genes. A) Identifying enhancer positive fragments. 3,428 of 
26,046 FAIRE regions were enriched in reporter vectors that were able to drive GFP expression 
in both orientations. B) 62% of these 3,428 enhancer positive fragments were in non-promoter 
intergenic regions. C) On average, enhancer positive fragments were further away from TSSs 
than FAIRE fragments or randomized FAIRE fragments. D) Genes near enhancer positive 
fragments were expressed at higher levels than other genes. 
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A total of 23,619 inserts (Table S2) were enriched in GFP-positive cells in the forward 
orientation, and 24,003 (Table S3) in the reverse orientation. Among these, 8,730 (Table S4) 
were held in common, meaning that they were associated with GFP-positive cells in both 
orientations. Of these 8,730, 3,428 overlapped with the 26,046 original stringently-called FAIRE 
sites and were also present in the entry and reporter libraries (Figure 3.3A). We refer to these 
3,428 fragments (Table S5) as “enhancer positive” from this point. 
3.3.3 Fragments positive for enhancer function tend to lie distal to transcription start sites 
We examined the genomic locations of these 3,428 enhancer positive regions. Nine 
percent were located within 2-kb upstream of RefSeq genes, which was about the same 
proportion as for FAIRE peaks in the starting FAIRE library (9.8%). It is known that promoter 
elements can act as enhancers, and that some enhancer elements are near transcription start sites 
(TSSs) [211]. Approximately 62% of the enhancer positives were located in non-promoter 
intergenic regions, relative to the expected null frequency of 58% (all genomic DNA) (Figure 
3.3B). We calculated the distance between each enhancer positive region to the nearest gene 
(Figure 3.3C, green). Similarly, we calculated such distance of FAIRE peaks (Figure 3.3C, 
red) and randomized FAIRE peaks (Figure 3.3C, black). FAIRE peaks were on average 70kb 
from the nearest TSS, while FAIRE peaks with randomized positions were 30kb away. In 
contrast, the 3,428 enhancer positive regions were located on average 210kb from the nearest 
TSSs, and the distribution of distances was strongly skewed toward longer fragments. This 
observation is consistent with enhancer positive regions functioning as regulatory elements that 
act at a distance. 
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3.3.4 Genes close to identified enhancer elements were relatively highly expressed 
To further assess evidence for enhancer function of the 3,428 positive regions, we 
assigned each to its nearest RefSeq gene as its putative target and determined expression levels 
of these target genes. Based on this mapping, 674 genes were associated with at least one 
enhancer positive regions, of which 114 (16.9%) were associated with more than three, with one 
gene TLE4 associated with 140 regions (Table S6). TLE4 (transducin-Like Enhancer Of Split 4) 
was shown to be highly expressed in HEK293 cells compared to other cell types [212]. This 
suggests enhancer positive regions may cluster and regulate common target genes, similar to 
previous observations in pancreatic islets [27]. More recently, blocks of active regulatory 
element super-enhancers were described in mouse and human ESCs, as well as in 86 diverse 
human cell types [176-178]. We hypothesized that associations with enhancer positive regions 
would result in higher expression of target genes.  To test this, we measured RNA levels in 
HEK293T cells using Affymetrix human exon arrays. We found that these 674 genes were 
expressed at significantly higher levels compared to expression levels of all genes (Figure 3.3D; 
t test, p-value < 2.2e-16). 
3.3.5 DNA motifs in identified enhancer elements 
We further interrogated the sequence composition of the identified putative enhancer 
elements by de novo motif analysis. Thirty-nine overrepresented motif sequences were found in 
those regions using the cERMIT [213] and CisFinder [214] software packages. Using STAMP 
[215], the closest matches in the TRANSFAC [57] or JASPAR [59] databases were returned for 
each de novo motif. Eleven transcription factor binding site motifs were found in the 
overrepresented de novo motifs (E-value < 1e-9) (Figure 4A). The motifs corresponding to the 
two most prominent known enhancer-binding factors were AP-1 and FoxA2. Activator protein 1 
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(AP-1) is a transcription factor complex comprised of members of the Fos/Jun family [216,217]. 
AP-1 has been shown to bind to enhancer elements and regulate gene expression in response to 
numerous stimuli [218-220] likely by maintaining chromatin accessibility [181]. Foxa2 is a 
transcriptional activator [221,222] [223] and a member of the forkhead class of DNA-binding 
proteins that has been shown to regulate nucleosome depletion  [221,224]. All of the factors that 
bind to the eleven enriched motifs are expressed in HEK293 cells [225,226]. An example of an 
enhancer-positive region containing an AP-1 binding site is shown in Figure 4B. This element 
appears to be open selectively in HEK293T cells, human embryonic stem cell line H1, cervical 
cancer cell line HeLa-S3, liver carcinoma cell line HepG2, and human umbilical vein endothelial 
cell line HUVEC, but not active in chronic myelogenous leukemia cell line K562 and 
lymphoblastoid cell line GM12878 (Figure 4B). 
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Figure 3.4. 3,428 enhancer positive fragments were enriched in transcription factor binding 
sites. A) Motifs of eleven transcription factors, including known enhancer binding factors AP-1 
and Foxa2, were found enriched in enhancer positive fragments. B) An example of AP-1 binding 
site in enhancer positive fragment upstream of SHC3 gene. 
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3.4 DISCUSSION 
Open chromatin regions identified by DNase I hypersensitivity or FAIRE often harbor 
active regulatory elements [6-8,14,25,27] that are used to regulate cell-type-specific gene 
expression. Using such methods, a large number of putative regulatory elements have been 
identified in projects such as ENCODE [29,31] and the Epigenome Roadmap [48]. Effective and 
practical high-throughput experimental methods that can functionally test these putative elements 
are urgently needed. In this study, we developed a highly parallel method for testing a large 
number of regulatory elements in a given cell type in a single experiment. As proof of concept, 
we performed this assay in the HEK-293 cell line using a library derived from FAIRE-enriched 
DNA fragments. We identified 3,428 FAIRE-enriched DNA elements with orientation-
independent enhancer activity. Our results demonstrate the feasibility of such high-throughput 
functional assays, which represent orders-of-magnitude improvement in functional 
characterization of regulatory elements over existing methods. Moreover, this assay can be easily 
modified to test for promoter, silencer and insulator function, and performed in other cells of 
interest.  
While there are many aspects of the method that could be improved (and are discussed 
below), it is important to point out the features of the experiment that are crucial to the success 
and general applicability of the assay. First, we used FAIRE DNA as starting material. To ensure 
that nearly all of the estimated 100,000 regulatory elements in a given cell type are cloned into 
the reporter vectors, and to preserve the library complexity during cloning steps, it is 
advantageous to start with a DNA library in which the ratio of regulatory DNA fragments to non-
regulatory DNA is as high as possible. It is also critical to start with a library that contains 
regulatory elements that are intact and have not been broken into non-functional fragments. 
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FAIRE isolates regulatory regions intact, enriches active regulatory regions 20 to 50-fold [14,26], 
and can be performed on both cultured cells and tissues.  In contrast, within a sheared or 
enzymatically digested genomic DNA library, or within a DNase HS library, regulatory elements 
are often cut or destroyed. Similarly, a library of ChIP fragments would contain only a fraction 
of all active regulatory regions, those that are associated with a particular regulatory factor of 
interest. In addition, the yield of ChIP is much lower than FAIRE and obtaining enough starting 
material (1-2 µg of DNA) for Gateway cloning can be challenging. Therefore, using FAIRE as 
staring material allowed us to build a putative regulatory element library of relatively high 
specificity and complexity. Second, we used the Gateway cloning system, which allows DNA 
fragments to be efficiently transferred between different reporter vectors. After DNA-fragments 
are cloned into the Gateway entry vector, the Gateway system makes downstream cloning for 
such high-throughput experiments fast and efficient. More importantly, it is easy to move the 
inserts to different reporter vectors so that in addition to the enhancer activity tested in this study, 
promoter, insulator or silencer function can be tested in parallel in future experiments. We also 
note that regulatory elements derived from tissues can be tested in comparable cell lines. 
While the initial results of this pilot study provide a proof of principle, some aspects of 
the design should be improved in future experiments. First, the sequencing libraries derived from 
the entry vector and both reporter vectors were made by shearing the entire construct (insert plus 
vector DNA), and the inserts in GFP-positive cells were recovered by a PCR product that 
included a significant part of the vector backbone and GFP gene along with the insert. As a result, 
our sequencing libraries contained inserts, vector sequences, and hybrids of insert and vector 
sequences. This made the rate of alignment to human genome low (Table 1). Attempts at 
computational processing of the reads to remove vector sequence were not effective. To 
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overcome this problem for these experiments we used a brute-force approach by sequencing each 
library to great depth and using only sequences that mapped perfectly to the human genome. To 
the extent this affected our sensitivity, it is possible that some regulatory elements were not 
recovered, or were not adequately enriched in aligned tags to be distinguishable from 
background. This problem can be avoided by optimizing primer design in future experiments. 
Second, GFP-negative cells contain important information and should be collected. Third, we 
used transient transfection to introduce reporter vectors into the testing cell line. Thus, multiple 
reporter vectors may enter a single cell during transfection. Although we tried to overcome this 
problem by performing three independent transfection experiments, and adopted stringent 
criteria in analysis on the combined dataset, it would be beneficial to employ a single-site stable 
integration scheme such as a lentiviral system [49,50]  in future experiments.   
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3.5 METHODS 
Cell culture.  Human embryonic kidney cell line HEK293T (Cat.#: HCL4517) were 
obtained from Open Biosystems (Part of Thermo Fisher Scientific) and cultured under 
recommended conditions using DMEM (Invitrogen, Cat.# 11995-065) supplemented with 10% 
Fetal Bovine Serum (Cellgro, Cat.# 35-016-CV), 2mM L-glutamine (Invitrogen, Cat.# 25030-
081), 50 units/ml penicillin and 50 g/ml streptomycin (Invitrogen, Cat.# 15140-122). 250 million 
cells were collected for FAIRE experiment.  
FAIRE-seq.  FAIRE-seq was performed as previously described [14,28]. Five 
independent FAIRE experiments were performed, each on 50M HEK293T cells. FAIRE DNA 
from five experiments were pulled and used for sequencing and Gateway cloning. 
Cloning of FAIRE fragments into the Gateway entry vector.  2 µg FAIRE DNA was 
used for Gateway cloning. FAIRE fragments were end repaired using Illumina library 
preparation reagents, ligated with adaptors containing BstX I sticky ends, and then cloned 
between BstX1 sites into Gateway entry vector pOTspnAttL. 
Cloning of FAIRE fragments from Gateway entry vector into Gateway reporter 
vectors.  2 µg FAIRE DNA was used for Gateway cloning. FAIRE fragments were end repaired 
using Illumina library preparation reagents, ligated with adaptors containing BstX I sticky ends, 
and then cloned between BstX1 sites into the Gateway entry vector pOTspnAttL.  
Cloning of FAIRE fragments from Gateway entry vector into Gateway reporter 
vectors.  Gateway destination vector pGL3-GFP was constructed using pGL3-Basic luciferase 
reporter vector (Promega, cat.# E1751). The luciferase gene was replaced with the GFP gene 
between NcoI and XbaI sites, the E1B basal promoter was cloned between BglII sites and 
HindIII sites 33-bp upstream of GFP gene, and the Gateway cassette of attR1-ccdB gene-attR2 
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was cloned into SmaI sites 69bp upstream of GFP gene. Vectors with the Gateway cassette 
inserted in both directions were confirmed by sequencing and named forward (attR1-R2-GFP) 
and reverse (attR2-attR1-GFP) vectors. FAIRE fragments were transferred into the pGL3-GFP 
forward and reverse vectors by Gateway recombination (Invitrogen).  
For positive control forward and reverse vectors, SV40 enhancer was cloned between 
Kpn and Sac sites 75bp upstream of GFP gene.  
Transfection of HEK293T cells using Lipofectamine.  Forward and Reverse reporter 
vectors containing FAIRE fragments, SV40 enhancer (positive control) or no insert (negative 
control) were used to transfect HEK293T cells. HEK293T were plated on 6-well plates at a 
density of 400,000 cells in 2 ml medium per well. For each 6-well plate, 24 µg Plasmid DNA 
was diluted into 1.5ml Opti-MEM reduced serum medium (Invitrogen, cat.#31985-070), and 
mixed with 60 µl Lipofectamine 2000 (Invitrogen, cat.# 11668-019) that was diluted in 1.5ml 
Opti-MEM reduced serum medium, and incubated at room temperature for 20 minutes. 500 µl of 
DNA/Lipofectamine mix was then added to each well. Cells were incubated at 37oC for 24 hours 
before the FACS assay. 
Detection of GFP-positive cells by fluorescence-activated cell sorting (FACS).  Cells 
were trypsinized and resuspended in DMEM without phenol red for the FACS assay. Gates were 
set to exclude cellular debris. Cells transfected with negative or positive reporter vectors were 
sorted first. The green fluorescent cell population of interest was gated based on light scatter and 
fluorescence. A threshold was chosen such that no negative control cells were in the P3 GFP 
bright region while ~5% of the positive control cells were. Cells were sorted at a rate of 2500–
3000 events/s. Only cells in P3 GFP-bright region were considered GFP-positive and were 
collected.  
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PCR amplification and high-throughput sequencing of FAIRE inserts.  GFP-positive 
cells were lysed by freezing and thawing five times. Cell lysate was used for PCR amplification. 
Primers flanking a ~650bp region that contained the FAIRE insert, part of GFP gene and part of 
vector backbone were used. To avoid over-amplification, 12, 14, 16, 18, 20, 22, 24 cycles of 
PCR amplification were tested first, and 16 or 18 cycles were chosen for each experiment, based 
on the number of cycles that gave the dimmest visible band when examined on gel. PCR 
products were then shared into approximately 100-200bp fragments and sequenced on Illumina 
GAII machines.  
Similarly, FAIRE inserts in the Gateway entry vector, forward and reverse reporter 
vectors were amplified using the same pair of primers, sheared, and sequenced. 
Sequencing data preprocessing. Sequencing data were processed and mapped to NCBI 
build 37/hg19 human reference genome using BOWTIE [51]. Reads with zero mismatch that 
were mapped to less than 4 places in the genome were used in downstream analyses. It should be 
noted that the percent of mapped reads of Gateway vector libraries and GFP-positive cell 
libraries were low (between 3%-20%) because most of the sequenced sheared PCR fragments 
were either from the vector backbone or a hybrid of FAIRE fragment and vector backbone and 
therefore could not be 100% mapped to the human genome. Genomic regions that were enriched 
in starting FAIRE library, forward GFP-positive cells, and reverse GFP-positive cells were 
identified by ZINBA [52] using FDR threshold 0.05.  
Overall comparison of enriched regions in FAIRE, forward GFP-positive, and 
reverse GFP-positive libraries.  Enriched regions in each library were compared using 
BEDTools suite (version 2.16.1) [53]. The results were plotted using Venn Diagram Plotter 
(http://omics.pnl.gov/software/VennDiagramPlotter.php). 
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Genome annotation.  Location of dDHS sites relative to genes was annotated using 
function annotatePeaks in HOMER (version v3.17) (Hypergeometric Optimization of Motif 
EnRichment) suite [54] with default UCSC RefGene annotation. The output of HOMER were 
processed using BEDTools suite (version 2.16.1). 
Microarray protocol and normalization.  Affymetrix Human Exon 1.0 ST microarray 
data were generated as described by Song et al. [7] from HEK293T cells.  Exon arrays were 
processed and normalized by Sheffield et al. [180].  Data are publicly available on the UCSC 
Genome Browser (http://genome.ucsc.edu) and GEO under accession number GSE15805.  
Thank you SS for the transforming scientific and life experience. You have taught me 
much about science, the human nature, and myself.   
Motif analysis.  DNA sequences of GFP positive regions were extracted from the UCSC 
Genome Browser. De novo motif search in dDHS sites was performed using cERMIT [213] and 
CisFinder [214]. The online version of CisFinder (http://lgsun.grc.nia.nih.gov/CisFinder/) was 
used with default parameter settings, except ‘‘clustered’’ motifs rather than the ‘‘elementary’’ 
ones. Top motifs from cERMIT and CisFinder were annotated using the STAMP web server 
(http:// www.benoslab.pitt.edu/stamp/) [215], with the ‘‘selected eukaryotic’’ option and 
searched in TRANSFAC [57] and JASPAR 2010 [59] databases.  
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CHAPTER IV: 
SPECIFIC HISTONE MODIFICATION PATTERNS MARK TRANSLOCATION 
BREAKPOINTS 
 
4.1 OVERVIEW 
Chromosomal translocations can disrupt normal gene function and result in fusion genes 
with new functions. Specific chromosome breakpoints and the formation of fusion genes are 
linked to various clinically defined cancers, and are shown to be the primary cause in many cases 
including subtypes of human leukemia and lymphoma. Genome-wide studies of chromosomal 
translocations suggest there exist DNA sequence-independent hotspots in the genome where 
translocations consistently recur. However, by which mechanisms translocations recur between 
certain genomic regions are still largely unknown. We hypothesized that susceptibility to 
chromosomal breakage is affected by chromatin structure marked by characteristic histone 
modifications. To test our hypothesis, we systematically analyzed public data from 
Roadmap Epigenomics of various histone modifications representing both active and repressive 
chromatin marks at 74 documented recurrent translocation breakpoint loci in hematopoetic 
cancers. We screened for histone modification patterns that may distinguish genes frequently 
involved in translocations from matched control genes in hematopoietic stem cells.  We found 
higher levels of monomethylated histone H3 lysine 4 (H3K4me1) at translocation genes and 
specific patterns compared to control genes. In addition, 15 translocation genes featured 
enrichment of both active chromatin mark H3K4me3 and repressive chromatin mark H3K27me3, 
which is commonly seen in genes poised for transcription. Taken together, our results suggest 
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that characteristic chromatin features marked by specific histone modifications are enriched at 
translocation genes involved in hematologic malignancies. This finding sheds lights on 
understanding the genomic hotspots of chromosomal translocations in oncogenesis, and can 
provide guidance for experimental validation of the role of predisposition of specific histone 
modifications prior to chromosomal translocations. 
4.2 INTRODUCTION 
Balanced chromosome translocations are the most common genetic aberrations found in 
hematologic malignancies [61-64,75,148,149,163] and are responsible for initiating 
tumorigenesis in some cases [61-64]. A marked feature of translocations in leukemia and 
lymphoma is that they are repeatedly observed in different patients with the same tumor type 
[61-64,75,149,227-229] [230]. Several studies have attributed the recurrence and non-random 
distribution of translocations to cell lineage- and tissue-specific genome organization and the 
spatial interaction of chromosomes [75,87,148,163,227,230-232]. While physical proximity is 
essential for the formation of translocations, and can determine which chromosomes fuse on a 
genomic level, the local factors that predispose genomic regions to chromosomal breakage and 
translocations remain to be elucidated [75,148,163]. 
It is evident that the initiating event for translocation formation is DNA double strand 
breaks (DSBs) at two or more genomic loci. DSBs can be induced by cellular stress, genotoxic 
stress, or endogenously during transcription and DNA replication processes. DSBs result in 
broken ends that can recombine legitimately to remain intact or illegitimately to form 
translocations [75]. Therefore, it was proposed that the recurrent pattern of translocations could 
be due to homologous DNA sequences at breakpoints that allow them to recombine 
illegitimately. However, sequencing studies have shown that while breakpoints do tend to cluster 
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in specific regions, ranging from a few hundred bases to more than 20 kb long, these regions are 
not defined by any consistent homologous sequences [61-64,161]. It has also been proposed that 
certain DNA sequence or structure variations could render stretches of DNA more vulnerable to 
breakage [75,148,163]. Recent studies have linked some breakpoints to common fragile sites that 
are enriched in AT-dinucleotide repeats, giving these regions high DNA helix flexibility and the 
ability to form secondary non-B DNA structures capable of inhibiting DNA replication 
[75,148,163]. Similarly, it has been shown that bcl1 and bcl2 breakpoints are enriched in CpG 
dinucleotide sequences and that the major breakpoint region of bcl2 adopts a stable non-B DNA 
structure that is targeted by the RAG endonuclease during B-cell lymphogenesis 
[75,148,161,163]. While these studies re-affirm that breakpoints occur in defined regions within 
the genome that may be more susceptible to DSBs and translocations, it has become clear that 
correlations with DNA sequence only apply to a limited number of genomic locations. 
Given the emerging role of chromatin in DNA accessibility and repair, and the fact that 
DSBs result in the context of chromatin, it seems plausible that the local chromatin environment 
could predispose certain genomic regions to breakage and translocations. In support of this view, 
genome-wide mapping of translocating regions after DSBs were introduced at c-myc or IgH 
suggest that translocations occur at higher frequency between transcriptionally active regions of 
the genome [75]. In addition, we recently found that the regions near translocation breakpoints in 
anaplastic large cell lymphoma (ALCL) are transcriptionally active prior to translocation 
formation. The implication of these studies is that the chromatin structure near breakpoints may 
be altered prior to translocation formation. 
One potential mechanism for a contribution of chromatin to DNA DSBs and translocation 
formation is via histone modifications. Histones make up the most basic unit of chromatin, the 
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nucleosome, around which DNA is wrapped. The highly basic amino terminal tails of histones 
project away from the nucleosome and are subject to post-translational modifications that include 
acetylation, methylation, and phosphorylation. Histone modifications have been shown to play a 
key role in determining higher-order chromatin structure and modulating DNA transactions such 
as transcription, replication, DNA repair, and access to enzymes and regulatory proteins [20,111]. 
In addition, histone modifications are thought to indicate chromatin status [20,31]. Modifications 
such as acetylation have been linked to decondensed chromatin states and active transcription, 
while condensed and transcriptionally silent regions are generally enriched in H3K9me3 marks 
[20,31]. However, it is apparent that the histone “code” is becoming more complex with 
evidence that histone modifications can act combinatorily to create “facultative” states in which 
it is not obvious whether a region is silent or active, condensed or decondensed. Even less is 
clear about whether histone modifications can define regions of increased DNA breakage and 
translocations.  
To date, histone modifications have been mapped only in a few breakpoints involved in 
hematopoietic cancers [48]. There has been no systematic demonstration of histone modification 
patterns in a comprehensive set of translocation genes involved in leukemias and lymphomas. 
Given the recently emerged role of chromatin structure in DNA damage and repair, we 
hypothesize that altered chromatin structure predisposes genomic sites to DNA breaks and 
translocations. To test our hypothesis, we leveraged existing databases containing information on 
chromosome translocations and genome-wide chromatin sequencing to map histone modification 
and DNaseI sites at the most common translocation sites. Our screening included active 
chromatin marks H3K4me1, H3K4me3, H3K27ac, H3K36me3, and DNaseI hypersensitivity 
sites, and repressive chromatin marks H3K9me3, and H3K27me3. We found that the majority of 
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translocation genes were located in chromatin regions defined by histone marks such as 
H3K4me1 that are traditionally associated with transcription and regulatory elements, and that 
some marks including H3K36me3 are more precisely found at breakpoints within these genes. 
Our results suggest that alterations in chromatin at the level of histone modifications are an 
important upstream event of translocations by making breakpoint regions vulnerable to DNA 
breakage and translocations.  
4.3 RESULTS 
4.3.1 Systematic comparative analysis to identify chromatin features that are enriched at 
recurrent chromosomal translocation sites in hematopoietic malignancies 
To test our hypothesis that specific chromatin structure predisposes genomic regions to 
chromosomal breaks and translocation, we applied a systematic bioinformatics approach to 
examine patterns of histone modifications and open chromatin profiles at genomic loci that were 
frequently involved in translocation in hematopoietic malignancies. We used CD34+ cells as our 
model system in this study. CD34+ cells represent immature hematopoietic stem cells that can 
differentiate to a variety of specialized blood cells or cells of the immune system. Many studies 
have suggested that chromatin architecture and histone modification patterns can be inherited 
from progenitor cells to differentiated cells [87]. Thereby, for translocations that occur in cells at 
more differentiated stages, such as BCR-ABL1 in chronic myeloid, and lymphoid progenitors, 
myeloids, and lymphoids, it is reasonable to examine the epigenetic states at those loci in their 
CD34+ hematopoietic stem cells. By interrogating the chromatin structure and histone 
modification profiles at genomic regions that were frequently involved in hematopoietic 
malignancies in CD34+ cells, we could gain insights on which chromatin features may be 
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enriched at translocation breakpoints and may potentially make those loci more vulnerable to 
double strand breaks than other genomic regions.  
We took advantage of the rich dataset on hematopoietic stem cells available in NIH 
Epigenomics Roadmap Project [48]. We chose the primary CD34+ cell line generated from a 33-
year-old female (see Methods). Among other CD34+ cell lines studied in Epigenomics 
Roadmap Project, this primary CD34+ cell line has the most extensive datasets including 
DNaseI-seq measuring chromatin accessibility, ChIP-seq data for active histone modifications 
H3K4me1, H3K4me3, H3K36me3, H3K27ac and repressive histone modifications H3K9me3, 
H3K27me3, reduced representation bisulfite sequencing (RRBS) data of DNA methylation, and 
mRNA-seq for transcription levels. To collect information on genomic loci that were frequently 
involved in chromosomal translocations in hematopoietic malignancies, we queried the 
Mitelman Database of Chromosome Aberrations that catalogs all reported cases of chromosomal 
translocations. We identified 74 RefSeq genes that were reported in at least 10 cases of 
hematopoietic malignancies (Table 4.1). Chromatin features such as histone modification and 
chromatin accessibly are closely linked to expression levels and genomic features of genes. 
Therefore, to identify chromatin features that may be preferentially enriched at those frequent 
translocation genes, for each translocation gene, we firstly defined a set of normal control genes 
that have similar gene expression level based on mRNA-seq data, and similar genomic features 
including 1) length, 2) percentage of transcript that is exonic , 3) number of exons, and 4) GC%. 
Up to 100 control genes were selected for each translocation genes (See Methods).  Altogether, 
5,076 control genes were selected for all 74 translocation genes (Supplementary Table 4.1).  
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4.3.2 Translocation genes are enriched for H3K4me1 in CD34+ cells 
We examined the chromatin accessibility and presence of histone modifications within 
gene bodies and their surrounding upstream and downstream 2kb regions. We will refer to those 
regions as gene +/- 2kb regions hereafter.  The levels of histone modifications and DNaseI 
hypersensitivity were measured by sequencing tag density (i.e. average number of sequencing 
tags normalized by the sequence depth). We compared the distribution of tag densities of each 
histone modification and DNaseI hypersensitivity in the gene +/- 2kb regions of 74 translocation 
genes and their 5076 control genes (Figure 4.1). Among the histone modifications examined, the 
population of translocation genes had a statistically significantly higher level of active mark 
H3K4me1 than the population of control genes (t-test p-value 0.00451; Wilcoxon test p-value 
0.00008). There was no statistically significant difference of the distribution or average levels of 
active marks H3K4me3, H3K36me3, H3K27ac and repressive marks H3K9me3 and H3K27me3 
between the translocation genes and control genes. Similarly, the distribution and average of 
DNase-I hypersensitivity levels were comparable between the translocation gene set and control 
gene set.  
Histone modification H3K4me1 has been shown to be a mark of active transcription and 
active enhancers. The enrichment of H3K4me1 in gene +/- 2kb regions of translocation genes in 
comparison to their control genes suggest a higher frequency of active enhancers present in 
translocation genes. A key characteristic of translocation events is the special proximity of 
genomic regions that contain the paired breakpoints in the nucleus, which can be measured by 
fluorescence in situ hybridization (FISH). Enhancers are thought to function by bringing distal 
regulatory elements into the proximity of gene promoters with bound transcription machinery, 
forming a loop-like structure. It is possible that translocation sites are enriched for active 
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enhancers that help bring translocation partners together and thereby facilitate the formation of a 
translocation.  
 
Figure 4.1. Comparison of histone modifications and DNase hypersensitivity signals in 74 
translocation genes and their 5076 control genes. Signal densities of H3K4me1, H3K4me3, 
H3K9me3, H3K27ac, H3K27me3, H3K36me3, and DNase HS in annotated gene +/-2kb were 
calculated (see Methods). The distributions of each mark in translocation genes and control 
genes were compared in the Kernel density plots. The x-axis of each plot is average read count in 
each gene (# of reads per kb). The distribution of H3K4me1 in translocation genes showed a 
statistically significant shift (t-test p-value 0.00451) from that in control genes. 
 
It should be noted that in this analysis translocation genes and control genes were 
compared as two aggregated populations. The 74 translocation genes had a broad range of 
expression levels in CD34+ measured by mRNA-seq. Since the level of histone modification and 
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chromatin accessibility is correlated with transcriptional activity, it is likely that both 
translocation gene sets and their control gene sets contain subpopulations of genes that have 
different patterns of histone modifications, as discussed in more detail below.  
4.3.3 Histone marks and DNase-I hypersensitivity defined subpopulations of translocation 
genes in CD34+ cells  
Translocation genes had varying expression levels in CD34+, which suggests that they 
may have distinct profiles of histone modifications and chromatin accessibility. To examine 
whether such subpopulations existed among 74 translocation genes, we compared each 
translocation gene to its corresponding set of control genes separately. For each histone mark or 
DNaseI hypersensitivity site, the tag density in the +/- 2kb region of each translocation gene was 
compared to the tag densities of its control genes (Supplementary Figure 4.1). The percentage 
of control genes for which tag densities were lower than that of the translocation gene was 
calculated (see Methods). 74 translocation genes were clustered by the patterns of their relative 
levels of histone modifications and DNaseI hypersensitivity compared to each of their own 
control genes (Figure 4.2). We find that there are subgroups of translocation genes that have 
higher H3K4me1, H3K4me3, and H3K27ac levels, but relatively lower H3K9me3 and 
H3K27me3 signals. 
As shown in the Figure 4.2, different translocation genes showed different patterns of 
chromatin signals. A sub-population consisting of 30 of the 74 translocation genes featured 
enrichment of active marks, namely levels of H3K4me1, H3K4me3, H3K27Ac, and DNaseI 
hypersensitivity.  For example, BCL2, BCL3, BCL6 all had relatively higher levels of H3K4me1, 
H3K3me3, and H3K27ac. Half of these 30 genes also had relatively higher signal of the active 
transcription mark H3K36me3 (top left cluster). About 20 genes showed relatively higher levels 
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of both active mark H3K4me3 and repressive mark H3K27me3.  It is possible that those genes 
had bivalent promoter domains that are marked by the coexistence of H3K4me3 and H3K27me3 
and may be “primed” for transcriptional activation. 
 
Figure 4.2. Comparison of histone modifications in individual translocation genes. Average 
read count for each histone modification and DNase HS in each translocation gene was 
compared to those in corresponding control genes. The percentile rank of a translocation gene 
among its control genes is plotted in the heatmap. Translocation genes were clustered and 
ordered using the overall ranking matrix (see Methods). 
 
Notably, majority of the 74 translocation genes had relatively higher level of H3K4me1 
than its control genes. The enrichment of H3K4me1 was frequently accompanied by enrichment 
of H3K4me3. This is consistent with the observation above that translocation genes had overall 
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higher level of H3K4me1 than control genes. This suggests that among genes with similar 
transcriptional activity, the level of H3K4me1 may distinguish those that are more prone to 
translocation from those that are not. Interestingly, some translocation genes, for example ALK, 
that were enriched for H3K4me1 and sometimes also H3K3me3 or DNase hypersensitivity were 
not appreciably expressed in CD34+, indicating that those genes were in a more open chromatin 
state even though they were not actively transcribed. It is possible that the more open chromatin 
state at those loci in combination with the presence of enhancer elements make those regions 
more vulnerable to translocation.  
4.3.4 Histone modifications around specific breakpoints 
Different histone modifications locate at different regions of genes and have different 
shapes of signals. H3K4me3 and H3K9me3 often have narrow peaky signals near transcription 
start sites (TSSs) of actively and inactively transcribed genes, respectively. H3K4me1 and 
H3K27ac co-localize with enhancer elements, which also have relatively narrow peak signals. 
H3K36me3 and H3K27me3 exhibit much broader signals along the entire gene body, with 
H3K36me3 marking actively transcribed genes and H3K27me3 marking transcriptionally 
repressed genes. All reported breakpoints in hematopoietic malignancies were mapped to introns 
of translocation genes. Studies have shown that histone modifications may have unique patterns 
at intron-exon boundaries and in introns. Such location information of histone modifications was 
not considered in the analyses above in which averaged signal density across the +/- 2kb 
promoter region was used. To truly understand the local chromatin environment and histone 
modification patterns at precise breakpoints, we decided to explore the strength and shape of 
each histone modification around actual annotated translocation sites. Coordinates of breakpoints 
in 19 of 74 translocation genes were collected from literature (see Methods; Supplementary 
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Table 4.2). We checked each gene and breakpoint region in the UCSC Genome Browser. Many 
of those gene mRNA annotations resulted from the sequencing of fusion genes or apparently 
truncated transcripts that corresponded to many of the breakpoint regions, showing that 
annotated start sites of these transcripts were adjacent to breakpoint regions we had. This 
supports the accuracy of the breakpoint information. 
Breakpoints were mapped to one or multiple introns in the 19 translocation genes, 
resulting breakpoint regions of lengths from ~1kb to ~229kb. Each breakpoint region was 
extended by 1kb on the 5' end and 1kb on the 3' end to also examine the surrounding chromatin 
environment. These will be referred to as breakpoint +/- 1kb regions hereafter.  For each 
breakpoint +/- 1kb region, to ensure the robustness of the results, two types of control regions 
were selected from control genes of each translocation gene: I) regions of the same relative 
length compared to the whole gene (control regions I); and (ii) regions of the same length 
(control regions II; see Methods). Each breakpoint region or control region was divided into 10 
equal-sized, non-overlapping windows. The histone modification signal density was calculated in 
each window and in the entire region.  
The overall density plots from the 19 breakpoint regions versus control regions were 
similar to the density plots from all 74 translocation genes versus control genes for most of the 
marks (Supplementary Figure 4.1). The results using control regions I and II were also 
comparable. There was not a single pattern that defined well all of the regions. Breakpoint 
regions seemed to be divided into those with very low histone mark signals relative to their 
control regions and those with enriched chromatin signals. For example, breakpoint regions of 
ABL1 (Supplementary Figure 4.2), PBX1, and BCL11B appeared to have lower levels of all 
histone modifications examined compared to their control regions. In contrast, some breakpoint 
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regions, such as HOXA11, PML, MLL, and BCR, had relatively higher levels of certain histone 
modifications than corresponding control regions. One of the primary differences when 
comparing the gene level plots and the region level plots was the H3K36me3 signal. Several 
breakpoints had relatively higher H3K36me3 signals, often accompanied by higher levels of 
H3K4me1 (e.g. HOXA11 in Figure 4.3.A), H3K27ac, and/or H3K4me3 (e.g. RARA in Figure 
4.3.B). Higher H3K4me1 or H3K4ac signals might reflect some higher order chromatin 
structures such as loop structures at active enhancers. These distinct histone modification 
patterns may also reflect the differences in chromatin marks between the 5'-gene and 3'-gene in a 
fusion gene pair. It is common that the 5’-gene in a fusion gene contributes an active promoter 
and is originally actively transcribed, while the 3’-gene is originally not transcribed. An example 
of such a translocation gene pair is NPM1-ALK. Indeed, NPM1 and ALK showed very different 
histone modification patterns at their breakpoint regions (unpublished data).  
  
	   97	  
 
Figure 4.3. Histone modification levels in 10 windows (see Methods) around the breakpoint 
(red) in genes HOXA11 (A) and RARA (B) compared to histone modification levels in 10 
windows from similar regions within 100 control genes of each gene (blue). Compared to control 
regions, breakpoint regions have relatively higher levels of H3K36me3 as well as H3K4me1 
(HOXA11), and H3K27ace and H3K4me3 (RARA). 
 
We reviewed each gene and breakpoint region in the UCSC Genome Browser with 
annotations from the Epigenomics Roadmap project, ENCODE project, and other datasets 
available in the UCSC Genome Browser. Consistent with the results above, there often appeared 
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to be a significant increase in this signal around the actual breakpoints. H3K36me3 has been 
recently reported to regulate DNA mismatch repair by recruiting MutSalpha, and that a lack of 
H3K36me3 results in a mutator phenotype. For double-stranded breaks and translocations, DNA 
repair acting downstream of the paired breaks is required for translocation formation. We also 
noticed that based on CTCF ChIP-seq experiments in other cell types (no data set was available 
for CD34+ cells), there seemed to be a lot of CTCF binding in the vicinity of these breakpoints, 
but usually not directly in the breakpoint region. CTCF has recently been shown to be involved 
in alternative splicing through bringing exons in close proximity to TSSs [85]. It may suggest 
that chromatin structure in terms of intra- and inter-chromosomal connections facilitated by 
CTCF may also play a role in translocation. More quantitative analyses are needed to further 
investigate the statistical significance of this. 
4.4 METHODS 
Datasets. We used RNA-, ChIP-, and DNase-seq data on a primary CD34+ cell line 
generated from a 33-year-old female (donor ID: RO 01549) available in NIH Epigenomics 
Roadmap Project (http://www.ncbi.nlm.nih.gov/geo/roadmap/epigenomics/). BED files of 
sequencing reads mapped to NCBI build 37/hg19 human reference genome from mRNA-seq 
(GSM909310), DNaseI-seq (GSM530657), and ChIP-seq data for active histone modifications 
H3K4me1 (GSM621451), H3K4me3 (GSM621439), H3K36me3 (GSM706843), H3K27ac 
(GSM772894) and repressive histone modifications H3K9me3 (GSM621436), H3K27me3 
(GSM706844) were used in analyses.  
Selecting control genes for translocation genes. For each translocation gene, we 
selected a set of control genes from human RefSeq genes (Release 57) [89,91] using the 
following criteria: each of 1) gene expression, 2) gene length, 3) percentage of transcript that was 
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exonic, 4) number of exons, and 5) percentage of G/C bases in each control gene was within +/- 
10 percentiles of the translocation gene among all RefSeq genes. RefSeq annotations were used. 
Gene expression was measured by RPKM (Reads per kilo base per million) calculated from 
mRNA-seq data. GC% was calculated using R package Repitools v1.4.0 [92]. If more than 100 
genes fulfilled the criteria, 100 genes with most similar gene expression levels were selected. 
Altogether, 5076 control genes were selected for all 74 translocation genes. 10 of the 74 genes 
had less than 100 control genes: SEPT9 (15 control genes), CBFA2T3 (20), PRDM16 (23), BCR 
(35), RARA (70), BCL2 (71), TCF3 (73), RUNX1 (76), ETV6 (87), HSP90AA1 (91). 
Measuring histone modification and chromatin accessibility levels in the gene body 
and promoter. Promoters were defined as transcription start sites (TSSs) +/- 2kb. Gene bodies 
were defined as transcribed regions +/- 2kb. For each translocation gene and each control gene, 
the number of mapped sequencing tags in gene body and the number in promoter from each 
ChIP-seq and DNase-seq dataset were calculated and normalized by the length of the region and 
the number of all mapped tags in each dataset. This normalized number of mapped sequencing 
tags was referred as tag density per kb and used to represent the level of histone modification or 
chromatin accessibility.  
Comparing translocation genes and control genes. Translocation genes and control 
genes were compared at both the population level and individual translocation level. The levels 
of histone modification and chromatin accessibility in gene bodies (defined as above) of 74 
translocation genes and 5076 control genes were compared by comparing the distribution of tag 
densities of each histone modification and DNaseI hypersensitivity. The density plots were 
generated using function density available in R statistical package (http://www.r-project.org).  
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The levels of histone modification and chromatin accessibility in the gene body and 
promoter of each translocation gene were compared to those of its selected control genes. For 
each histone modification or DNaseI, the tag density of the translocation gene was compared to 
the tag densities of its control genes and represented as boxplots using function boxplot in R. The 
percentage of control genes for which tag densities were lower than that of the translocation gene 
was calculated. 74 translocation genes were clustered using patterns of their relative levels of 
histone modifications and DNaseI hypersensitivity compared to their control genes using 
function hclust available in R. Heatmaps were generated using R package ggplot2 v0.8.9 
(http://ggplot2.org/).  
Measuring histone modification and chromatin accessibility levels around 
breakpoints. Coordinates of breakpoint regions in 15 translocation genes were collected from 
literature. Each breakpoint region was extended by 1kb on the 5' end and 1kb on the 3' end 
(referred as breakpoint +/- 1kb region).  
For each breakpoint +/- 1kb region, the breakpoint start position compared to the TSS, 
the fraction of the gene covered by the breakpoint region, and the breakpoint mid-point position 
compared to the TSS were calculated. For example, one breakpoint region could start at a 
position that was at 10% (of the length of the gene) downstream of TSS with a length equal to 
20% of the total gene length and whose midpoint is 20% downstream of TSS. Control 
"breakpoint" regions from each control gene were selected in two different ways to ensure the 
robustness of the results:  1) Control breakpoint region of same relative size compared to length 
of control gene: For each control gene, a breakpoint region was defined at the same relative 
position as in the true breakpoint gene. For the example above, the region would start at the base 
pair corresponding to 10% of the control gene length from the TSS, and the size of the region 
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was of 20% of the control gene size. It should be noted that the length of each selected control 
breakpoint region was different and not equal to the size of the true breakpoint region due to 
differences in control gene sizes; and  2) Control breakpoint region was the same size as the true 
breakpoint region: For each control gene, a breakpoint region of the same absolute length as the 
true breakpoint region was selected. The selected region was centered at the same relative 
position in the control gene based the position of the center of the true breakpoint region within 
the translocation gene. For example, if the true breakpoint region was 5kb long and was centered 
at a position 20% of the length of translocation gene from the TSS, the control breakpoint region 
was defined as a 5kb region centered at the position 20% of the length of the control gene from 
the TSS. In this case, the lengths of breakpoint region and its control regions were the same.    
Each breakpoint region or control region was divided into 10 equal-sized, non-
overlapping windows. The tag density per kb (defined as above) of each histone modification 
and DNaseI was calculated in each window. Tag densities in windows of each breakpoint region 
were compared to those of control regions.  
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4.5 SUPPLEMENTAL DATA 
HOXA13 ARHGAP26 CEBPA FUS 
TLX1 PVT1 HOXA10 MLLT3 
HOXA11 BCL6 MYO1F CBFB 
RUNX1T1 BCL2 JAK2 RUNX1 
ALK KIF3B RBM15 MYC 
BCL11B DCPS MKL1 HOXA9 
CCND1 BCL9L ZCCHC7 RPN1 
FGFR3 MALT1 PML SEPT11 
CEBPE ZBTB16 PBX1 ETV6 
ID4 RARA SEPT9 GSTP1 
CRLF2 MECOM TCF3 LMO2 
RALGPS1 WHSC1 CEBPG DEK 
PAX5 SH3GL1 HLF HSP90AA1 
HOXA2 CBL CBFA2T3 NPM1 
PRDM16 BCL3 MLL  
CEBPD ABL1 NUP98  
MYH11 CREBBP EPS15  
MLLT4 TTL BCR  
TIRAP MLLT1 ERG  
ELL NUP214 AFF1  
 
Table 4.1: 74 translocation genes. 
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Translocation gene Chromosome Breakpoint Start Breakpoint Stop Information 
BCR chr22 23630284 23637342 Intron 13-17 
ETV6  chr12 12006496 12037378 Intron 4 and 5 
NPM1 chr5 170818804 170819713 Intron 4 
DEK chr6 18226474 18236682 Intron 9 
HOXA9 chr7 27203461 27204496 Intron 1 
ALK chr2 29446395 29448326 Intron 19 
BCL11B chr14 99642533 99697681 Intron 3 
ARHGAP26 chr5 142500713 142513531 Intron 18 
HOXA11 chr7 27222648 27224054 Intron 1 
SEPT11 chr4 77871084 77917577 Intron 1 
PML chr15 74325756 74326818 Intron 6 
RARA chr17 38487649 38504567 Intron 2 
TCF3  chr19 1615821 1619109 Intron 16 
PBX1 chr1 164532549 164761730 Intron 2 
ABL1 chr9 133589843 133729451 Intron 1 
CBFB chr16 67116212 67132612 Intron 5 
MYH11 chr16 15815278 15818850 Intron 28-32 
RUNX1 chr21 36206899 36231770 Intron 21 
MLL chr11 118353137 118359475 Intron 11 
 
Table 4.2: Breakpoints in 19 translocation genes. 
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Figure 4.4. Comparison of histone modifications and DNase hypersensitivity signals in 
breakpoint regions of 19 translocation genes and control regions of their control genes. 
Signal densities of H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3, H3K36me3, and 
DNase HS in documented breakpoints +/-1kb were calculated (see Methods). The distributions 
of each mark in translocation genes and control genes were compared in the Kernel density plots. 
The x-axis of each plot was average read count in each gene (# of reads per kb). The distribution 
of H3K4me1 in translocations genes showed a statistically significant shift from that in control 
genes. 
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Figure 4.5. Histone modification levels in 10 windows (see Methods) around the breakpoint 
in gene ABL1 (red) compared to histone modification levels in 10 windows in control regions of 
100 control genes (blue). ABL1 breakpoint has no characteristic histone modification profile 
compared to its control regions. 
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CHAPTER V: 
DISCUSSION AND PERSPECTIVES 
 
Our genome-wide mapping and comparison of open chromatin in human ESCs and iPSCs 
provide rich datasets on chromatin structures in pluripotent cells, and illustrate the impact 
on pluripotency and transcription regulation during cellular differentiation.  
Open chromatin regions demarcate active regulatory elements. Different cell types have 
distinct open chromatin profiles, indicating that different subsets of regulatory elements are 
utilized for precise regulation of cell-type-specific gene expression. Pluripotent stem cells have a 
unique gene expression profile dictated by its unique chromatin architecture that directly reflects 
their pluripotent identity. Both previous and our studies suggest that the pluripotency of 
embryonic stem cells is largely obtained and maintained by acquiring a particularly “open” state 
of chromatin. Although hiPSC lines are capable of differentiating into different cells types and 
are thus pluripotent, they often behave differently than hESCs during and/or after differentiation 
into one or a few specific cell lineages. Such observations suggest that while cells acquired 
pluripotency after reprogramming, some fine-tuning of the cell identity and function is not fully 
achieved. Specifically, reprogrammed cells are often shown to carry epigenetic “memories” of 
their cell of origin. It has been suggested that some of the parental memories are inherited 
through reprogrammed cells carrying residuals of DNA methylation patterns of parental cells. In 
other words, incomplete or incorrect reset of DNA methylation, even subtle, may lead to 
incomplete reacquisition of pluripotency through reprogramming.  
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Chromatin in somatic cells also needs to be accurately re-configured to a “pluripotent” 
open state to achieve complete reprogramming. Our results support the idea that establishing a 
permissive chromatin state precedes differentiation, and that incomplete establishment of that 
chromatin state can impede the efficiency of iPSC differentiation. Specifically, (1) sites that are 
not completely reprogrammed in iPSCs tend to have characteristic chromatin profiles in the 
parental somatic cells, and (2) the identification of incompletely reprogrammed sites in induced 
pluripotent cells can be instructive in predicting variations with gene regulation upon iPSC 
differentiation. We expect that analysis of additional hiPSCs and hESCs will identify 
overlapping sets of dDHS sites with properties similar to those described here, and we predict 
that dDHS sites shared by hiPSC lines will be enriched in dCOREs. The exact identity of 
differences in individual iPS lines will likely affect the efficiency of differentiation into specific 
somatic lineages.  Our identification of regulatory regions that are refractory to reprogramming 
and their properties will be critical to the understanding and use of iPSCs and embryonic stem 
cells. 
In general, an important question when comparing iPSCs and ESCs is, which differences 
are functionally relevant? Genomic abnormalities occur in any cell culture including ESCs. 
Nonpathogenic variations may also occur in vivo such as in blood or bone marrow cells that have 
been used for transfusion or transplantation to treat patients for decades. Some genomic 
variations in iPSCs may be unpreventable and harmless for their use in regenerative medicine. 
Open chromatin maps have been used to guide the identification of functional SNPs that are 
strongly associated with type II diabetes. The rationale is, active regulatory elements reside in 
open chromatin regions and thus SNPs that are located in open chromatin regions may be 
associated with regulatory elements and thus functional. The same rationale can be used to 
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annotate genetic and epigenetic variation in iPSCs to differentiate functional and non-functional 
variation. We have shown that several differential DHS sites we identified overlap with 
previously identified differentially methylated regions between hESCs and hiPSCs. DNase or 
FAIRE in combination with quantitative PCR, microarray, or high-throughput sequencing can 
quantitatively assay chromatin accessibility at those loci in iPSC lines or any pluripotent cell 
lines in general. This can be implemented in a workflow for high-throughput screening and 
characterization of human pluripotent cell lines [88]. 
Genome-wide high-throughput functional annotation of regulatory elements is the key to 
annotation of human genome   
Genome-wide experiments such as DNase I-, FAIRE-, and ChIP-seq experiments provide 
evidence for the genomic locations of >100,000 active DNA regulatory elements present in each 
human cell type [8,31]. A weakness of these assays is that they do not indicate the precise 
regulatory function of identified DNA elements, and this has been a major bottleneck in 
characterizing human genome function. Here we presented a method for the highly parallel 
measurement of the functional activity of putative regulatory elements isolated from open 
chromatin. It enables us to annotate the function of thousands of putative human regulatory 
elements in one single experiment, representing orders-of-magnitude improvement in functional 
characterization of regulatory elements over traditional reporter assays. This study is especially 
timely given the recent publication of massively parallel reporter assays that interrogate the 
enhancer activity of tens of thousands of synthesized DNA sequences[95,97,98]. These studies 
demonstrate the feasibility and great value of high-throughput annotation of enhancer elements. 
However, such synthesis-based approaches require the knowledge of exact DNA sequences of 
tested elements prior to the assay, and are designed to test the activities of variants of known 
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enhancers or putative enhancers. It is thus hard and costly to adapt such strategies to dissect 
native regulatory elements that are active in a given cell type. In contrast, our design combines 
the use of FAIRE to isolate intact native regulatory elements genome-wide that are active in a 
given cell type, and a highly parallel enhancer reporter assay of these elements. More 
importantly, our approach can be used to annotate native regulatory elements derived from 
tissues in comparable cell lines. Although there were several flaws in the design of our initial 
experiment as discussed in Chapter III, we are confident that with the modifications we proposed 
and different reporter constructs, this approach can be broadly applied to test the function of all 
putative regulatory elements that are active in the tested cell line, with the number likely on the 
order of 1,000-10,000.  
In addition, this method is versatile and can be easily adapted to test promoter, insulator, 
or silencer function of regulatory elements (Figure 5.1). In combinations with different reporter 
Gateway vectors, FAIRE fragments in one Gateway entry vector can be easily transferred to 
different reporter vectors to test for promoter, enhancer, insulator, and silencer function in 
parallel. In our study, we used an enhancer reporter construct (Figure 5.1B). It is feasible to 
build on existing constructs and elements of known behavior to build reporters for promoters, 
enhancers, silencers and insulators, as illustrated in Figure 5.1. For promoter activity, sequences 
can simply be cloned upstream of the reporter (Figure 5.1A). Testing for silencer activity 
(Figure 5.1C) can be challenging. One possibility is to use the well-annotated beta-globin locus. 
The silencer activity of fragments can thus be measured by their ability to quench transcription 
from beta-globin promoter region (spanning from -255 to +50 containing the TATA box (-30nt), 
CAAT box (-70nt), and CAC box motif (-90nt), which are necessary for efficient transcription) 
127-129. The native “Silencer II” element that naturally located between -302 and -294nt (5’-
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TTCAATATG-3’) upstream of human adult beta-globin gene can be used as a positive control. 
Such silencer system has been shown to work in other cell types 132. The E1B promoter used in 
our existing enhancer reporter construct can be used in the insulator assay (Figure 5.1D). Known 
insulator elements such as the chicken HS4 beta-globin 5' boundary element 17,133 can be used 
as positive controls. Data collected from such assays of different regulatory actives will provide 
a far more complete inventory of the location and function of regulatory elements in the tested 
cell line.  
 
 
 
 
 
 
 
 
Figure 5.1. Schematic representation of reporter constructs to be employed for 
identification of regulatory function. The expected result, GFP positive (green) or negative 
(white) is indicated for negative controls, positive controls, and the tested fragments. * indicates 
use in initial experiments. 
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